

Subject Index—Volume 95

- No. 1, July 1, pp. 1–208
 No. 2, July 15, pp. 209–450
 No. 3, August 1, pp. 451–674
 No. 4, August 15, pp. 675–906
 No. 4, August 15, Supplement, pp. 907–946
 No. 5, September 1, pp. 947–1184
 No. 6, September 15, pp. 1185–1396
 No. 7, October 1, pp. 1397–1610
 No. 8, October 15, pp. 1611–1816
 No. 9, November 1, pp. 1817–2040
 No. 10, November 15, pp. 2041–2256
 No. 11, December 1, pp. 2257–2444
 No. 12, December 15, pp. 2445–2582

A

- Acidosis, in glioma, effects on growth and radiochemo-sensitivity in, 1113
 Acquired immunodeficiency syndrome
 central nervous system lymphoma in, incidence of, 193
 Kaposi sarcoma in
 liposomal tretinoin for, 2555
 paclitaxel for, 147
 Actinomycin D, with 5-fluorouracil, for gestational tro-phoblastic tumors, 1051
 Activity, cancer incidence and, 1134
 Acute leukemia. *See* Leukemia
 Adenocarcinoma. *See specific sites*
 Adenomas, pituitary
 prolactin-secreting, clinicopathology of, 258
 radiation exposure and, 397
 Adhesion-regulated proteinase, decreased production of,
 in oral cancer, 2524
 Adolescents. *See also* Children
 long-term survivor, pulmonary complications in, 2431
 metastatic sarcoma in, peripheral blood stem cell
 support for, 1354
 thyroid cancer in, 724
 Adrenal insufficiency, in bone marrow transplant recipi-
 ents, 1076
 African Americans. *See also* Race/ethnicity
 breast cancer in
 screening for, 8
 survival in, 1988
 in early-stage disease, 1759
 in young women, 21
 ovarian cancer in, incidence of, 2380
 Age. *See also* Children; Elderly
 hepatocellular carcinoma development in chronic hep-
 atitis C and, 331
 Aggressive fibromatosis, extraabdominal, imatinib mesy-
 late for, 2373
 AIB1, in hepatocellular carcinoma, 2346
 AIDS
 central nervous system lymphoma in, incidence of, 193
 Kaposi sarcoma in
 liposomal tretinoin for, 2555
 paclitaxel for, 147
 Alcohol use/abuse, hepatocellular carcinoma develop-
 ment in chronic hepatitis C and, 331
 Alopecia, in chemotherapy, patient perceptions of, 155
 5-Aminolevulinic acid, in diagnosis of premalignant
 urothelial lesions, 1234
 Amphetamines, in pregnancy, acute lymphoblastic leu-
 kemia in offspring and, 1786
 Analgesia
 dextromethorphan in, for orthopaedic oncology pa-
 tients, 1164
 intravenous morphine with rapid titration for, 203
 topical, for mucositis, in head and neck cancer, 2230
 Anastrozole
 pharmacology and pharmacokinetics of, 2006
 vs. tamoxifen, for breast cancer, 2442 (letter)
 Androgen blockade, for prostate cancer
 anemia after, prognosis and, 275
 bone density and body fat after, 2136
 in combined vs. monotherapy, 209 (editorial), 361
 quality of life and, 287
 Anemia
 in lung cancer, darbopoietin- α for, 613
 in platinum-based chemotherapy, epoetin- α for, 2408
 in prostate cancer, prognosis and, 275
 quality of life and, 888
 Angiogenesis
 in acute myeloid leukemia, prognosis and, 1911
 in bronchial epithelium of smokers, 1539
 in endometrial cancer, hypoxia-inducible factors 1 α
 and 2 α and, 1055
 in hepatocellular carcinoma, serum endostatin and,
 2188
 in lung cancer, CT evaluation of, 835
 in myelodysplastic syndromes, prognosis and, 1911
 in renal cell carcinoma, 47
 Antigens. *See specific tumor antigens*
 Apoptosis
 in endometrial cancer, 1463
 in hepatocellular carcinoma
 gene expression and, 1939
 β 1-integrin-related resistance to, 896

- peroxisome proliferator-activated receptor gamma ligand for, 2243
- Rel/NF-kappaB and, 1696
- in testicular cancer, Fas/Fas ligand system in, 73
- Ara-C. *See* Cytarabine
- Arm problems, after axillary node dissection, in older women, 2445
- Aromatase inhibitor(s)
 - pharmacology and pharmacokinetics of, 2006
 - for prostate cancer, 1865
- Arterial embolization, for giant cell tumor of sacrum, 1317
- Ashkenazi Jews, with BRCA1 mutation, tumor morphology and HER/*neu* status in, 2068
- Asian/Pacific Islanders, breast cancer in, treatment disparities in, 2257 (editorial), 2268
- Aspiration biopsy. *See also* Biopsy
 - ultrasound-guided, of axillary nodes, in breast cancer, 982
- Astrocytoma, *p53* mutations in, survival and, 249
- Autologous stem cell transplant. *See also* Stem cell transplant
 - for chronic myeloid leukemia, 2339
- Axillary node dissection. *See also* Lymph node biopsy
 - complications of, in older women, 2445
 - lymphedema after, intermittent pneumatic compression for, 2260
 - vs. sentinel node biopsy, 478

B

- Barrett esophagus, endoscopic screening/surveillance for, 32
- Basic fibroblast growth factor
 - in acute myeloid leukemia, prognosis and, 1911
 - in myelodysplasia, prognosis and, 1911
- bax*
 - in endometrial hyperplasia/carcinoma, 1463
 - in hepatocellular carcinoma, 1938
- bcl-2*
 - in endometrial hyperplasia/carcinoma, 1463
 - in hepatocellular carcinoma, 1938
- BCR-ABL-transfected cells, reduced focal adhesion kinase and paxillin phosphorylation in, 440
- Benzo[*a*]pyrene diol epoxide (BPDE), head and neck cancer and, 563
- Bereaved parents, cancer in, 2237
- β -2-microglobulin, in Hodgkin's disease, prognosis and, 2534
- β -catenin, in colorectal cancer, prognosis and, 2479
- Biliary cancer, *H. pylori* infection and, 1946
- Biocompression, for lymphedema, 2260
- Biopsy
 - of prostate, age- and volume-adjusted, 2112
 - sentinel node. *See also* Lymph node dissection
 - vs. axillary dissection, in breast cancer, 15
 - in ductal carcinoma in situ, 15
 - in melanoma, unusual sites for, 354
 - ultrasound-guided fine-needle, of axillary nodes, in breast cancer, 982
- Blacks. *See also* Race/ethnicity
 - breast cancer in
 - screening for, 8
 - survival in, 1988
 - in early-stage disease, 1759
 - in young women, 21
 - ovarian cancer in, incidence of, 2380
- Bladder
 - neuroendocrine tumors of, morphology and treatment of, 1415
 - preinvasive lesions in, 5-aminolevulinic acid in diagnosis of, 1234
- Bladder cancer
 - gelsolin and e-cadherin in, 1247
 - gemcitabine and epirubicin for, 1444
 - HER/*neu* in, prognosis and, 1009
 - hyaluronic acid-hyaluronidase and BTA-Stat tests for, 61
 - nitric oxide in, 2293
 - in postmenopausal women, risk factors for, 2316
 - pretreatment prognostic factors in, 751
 - proline-directed protein kinase F_{λ} in, 775
 - with renal dysfunction, paclitaxel and carboplatin for, 1022
 - superficial, recurrence of
 - multiple sequential, 1239
 - predictors of, 784
 - thymidine kinase in, prognosis and, 2120
 - urokinase-type plasminogen activator in, 2494
- Bleomycin
 - for Hodgkin's disease, with radiotherapy, 2169
 - for uveal melanoma, 2366
- Body fat, after androgen blockade for prostate cancer, 2136
- Bone density, after androgen blockade for prostate cancer, 2136
- Bone marrow transplant. *See also* Stem cell transplant
 - cognitive function and, 183
 - endocrine dysfunction after, 1076
- Bone metastasis
 - in lung cancer, parathyroid hormone-related protein and, 1706
 - in prostate cancer, 1028
 - urinary calcium excretion in monitoring of, 1182 (letter)
- Bone tumors, pain management in, dextromethorphan in, 1164
- Bowel dysfunction, prostate cancer treatment and, 82
- BPDE-induced lymphocytic 3p21.3 aberrations, head and neck cancer and, 563
- Brachytherapy. *See also* Radiation therapy
 - for prostate cancer, patient selection for, 513
- Brain metastasis
 - from esthesioneuroblastoma, treatment of, 243
 - in nonsmall cell lung cancer, 605
- Brain tumors
 - esthesioneuroblastoma, treatment of, 243

- glioblastoma, *p53* mutations in, survival and, 249
- gliomas
- acidosis effects on growth and radiochemosensitivity in, 1113
 - in vivo models of, chemosensitivity testing in, 641
- gliomatosis cerebri, radiotherapy for, 2027
- medulloblastoma, *Gli3* mutations in, 28
- metabolic characterization of, in children, 1376
- refractory pediatric, fotemustine for, 1294
- supratentorial neuroglial, clinical and survival covariates in, in children, 1302
- Breast cancer
- anastrozole vs. tamoxifen for, 2442 (letter)
 - in Ashkenazi Jews with *BRCA1* mutation, *HER/neu* and tumor morphology in, 2068
 - in Asian/Pacific Islanders, treatment disparities in, 2257 (editorial), 2258
 - axillary node dissection in
 - complications of, in older women, 2445
 - lymphedema after, intermittent pneumatic compression for, 2260
 - chemotherapy for
 - pathobiology of, 681
 - with radiotherapy, 681
 - clinical trials in, exclusion of elderly from, 989
 - CYFRA 21-1 in, 670 (letter)
 - ductal fluid specimens in, protein expression patterns in, 2276
 - ductal in situ, sentinel node biopsy in, 15
 - early-stage, treatment and survival in, racial differences in, 1759
 - erythropoietin and erythropoietin receptor in, 969
 - fatigue in, 2017
 - histology of, detection method and, 470
 - hormone replacement therapy and
 - in breast cancer survivors, 1817
 - in Hispanic vs. non-Hispanic women, 960
 - histologic type and, 2455
 - lymphedema in, intermittent pneumatic compression for, 2260
 - mammogram-detected, provider case volume and outcome in, 704
 - mastectomy for
 - choices influencing patient choice of, 1185
 - for Paget disease, 1
 - prophylactic bilateral, 236
 - nitric oxide and nitric oxide synthase in, 1191
 - in older patients, adjuvant tamoxifen for, 2465
 - paclitaxel and cisplatin for, 2044
 - prevalence of, interstate comparisons of, 430
 - primary chemotherapy for, 228
 - prophylactic bilateral mastectomy for, 236
 - screening for
 - cancer detected on, provider case volume and outcome in, 704
 - delay to diagnosis after, prognosis and, 2254 (letter)
 - histologic findings and, 470
 - interval adherence for, 219
 - population mortality impact of, 451 (editorial)
 - racial vs. regional differences in, 2211
 - for underserved population, 8
 - second primary
 - mortality in, 2051
 - vs. true local recurrence, 2059
 - sentinel node biopsy in, vs. axillary dissection, 478
 - serum interleukin-18 and nitric oxide in, 663
 - surgery for, factors influencing patient choice in, 1185.
See also Breast conservation surgery; Mammography
 - survival in, race/ethnicity and, 21, 1401, 1759, 1988
 - survivors of, estrogen replacement therapy, 1817
 - treatment of, racial differences in, 1401
 - tumor size in, survival and, 713
 - ultrasound-guided fine-needle aspiration of axillary nodes in, 982
 - in young women, survival in, ethnicity and, 21
- Breast conservation surgery
- choices influencing patient choice of, 1185
 - local recurrence after, vs. new primary, 2059
 - second primary after
 - mortality and, 2051
 - vs. true local recurrence, 2059
- Breast tumors, benign, nitric oxide and nitric oxide synthase in, 1191
- Bronchial epithelium, neoangiogenesis and proliferative response in, of smokers, 1539
- BTA-Stat test, in bladder cancer, 61
- C
- CA125, in ovarian cancer, 1886
- Calbindin-D_{28k}, in medulloblastoma, prognosis and, 404
- Camptothecin derivatives, with gemcitabine, for pancreatic cancer, 923
- Cancer
- advanced, pegylated liposomal doxorubicin and gemcitabine for, 2223
 - in bereaved parents, 2237
 - after hyperparathyroidism, in Denmark, 1611
 - physical activity and, 1134
 - prevalence of, interstate comparisons of, 430
- Carboplatin
- for advanced cancer, with paclitaxel, 2000
 - for germ cell tumors, 309
 - for head and neck cancer, 322
 - for intracranial esthesioneuroblastoma, 243
 - for nonsmall cell lung cancer, 1279
 - with irinotecan and paclitaxel, 1520
 - for urothelial cancer, with renal dysfunction, 1022
- Cardiotoxicity, of trastuzumab, 1592
- β -Catenin, in colorectal cancer, prognosis and, 2479
- CCND1* numerical aberration, in oral cancer, prognosis and, 2152
- Cell strains, sarcoma, 1560
- Cell surface proteins, in nodal metastasis in oral cancer, 1663
- Central nervous system lymphoma

- primary, incidence of, 193, 1505
- prophylactic intrathecal methotrexate and hydrocortisone for, 576
- Central nervous system prophylaxis
 - cognitive impairment and, in acute lymphoblastic leukemia survivors, 2562
 - cranial nerve palsy and, 404
 - in lymphoma, intrathecal methotrexate and hydrocortisone for, 576
 - pituitary adenoma and, 397
- Central nervous system recurrence
 - in esthesioneuroblastoma, treatment of, 243
 - for non-Hodgkin's lymphoma, prophylactic intrathecal methotrexate and hydrocortisone in, 576
 - in nonsmall cell lung cancer, 605
 - prevention of. *See* Central nervous system prophylaxis
- Cerebral metastasis
 - from esthesioneuroblastoma, treatment of, 243
 - in nonsmall cell lung cancer, 605
- Cervical cancer
 - cyclooxygenase-2 in, prognosis and, 531
 - screening for
 - in oncogenic HPV-infected women, 2145
 - race/ethnicity and, 2211
 - racial vs. regional differences in, 2211
- Cetumixab, for pancreatic cancer, with gemcitabine, 923
- Chemoimmunotherapy, for uveal melanoma, 2366
- Chemoradiotherapy
 - for breast cancer, 681
 - for gliomas, acidosis and, 1113
 - for head and neck cancer, 1472
 - mucositis in, topical morphine for, 2230
 - for Hodgkin's disease, 2169
 - for pancreatic cancer, 933
- Chemosensitizers, for multidrug resistance, in hepatoblastoma, 1795
- Chemotherapy. *See also specific agents*
 - for acute lymphoblastic leukemia, in adults, 581
 - for advanced cancer, 2000
 - anemia and. *See* Anemia
 - for breast cancer, 2044
 - pathobiology of, 681
 - as primary therapy, 228
 - with radiotherapy, 696
 - clinical trials of. *See* Clinical trials
 - for colorectal cancer, socioeconomic and demographic factors in, 39
 - for germ cell tumors, 309, 1879
 - for gestational trophoblastic tumors, 1051
 - for gliomas
 - acidosis and, 1113
 - testing of in in vivo models of, 641
 - hepatic arterial infusion, for hepatocellular carcinoma
 - with portal vein tumor thrombosis, 588
 - for hepatic metastasis, in colorectal cancer, 2283
 - for hepatoblastoma
 - in children, 172
 - resistance to, *MDR1* gene and, 1795
 - for hepatocellular carcinoma
 - with portal vein tumor thrombosis, 588
 - prognostic factors in, 2038 (letter)
 - with immunotherapy. *See* Chemoimmunotherapy
 - for intracranial neuroblastoma, 243
 - for multiple myeloma, 2160
 - for nasopharyngeal cancer, 2516
 - for non-Hodgkin's lymphoma, for CNS prophylaxis, 576
 - for nonsmall cell lung cancer, 340, 1520, 1714
 - for osteosarcoma
 - of head and neck, 1495
 - without surgery, 2202
 - for ovarian cancer, 1656
 - for pancreatic cancer, 908, 912, 923, 928, 933, 941
 - with radiotherapy, 933
 - peripheral blood stem cell support in, in pediatric sarcoma, 1354
 - platinum-based, anemia in, epoetin- α for, 2408
 - postoperative adjuvant, for gallbladder cancer, 1685
 - pulmonary complications of, in long-term pediatric survivors, 2431
 - with radiotherapy. *See* Chemoradiotherapy
 - for renal cell carcinoma, with immunotherapy, 1644
 - for rhabdomyosarcoma, in adults, 377
 - side effects of, patient perceptions of, 155
 - for small cell lung cancer, 1511
 - for soft tissue sarcoma, radiographic response to, prognosis and, 1120
 - for spinal cord ependymoma, 997
 - for urothelial cancer, with renal dysfunction, 1022
- Chest irradiation, complications of, in long-term pediatric survivors, 2431
- Children. *See also Adolescents and specific cancers, e.g., Leukemia*
 - brain tumors in, metabolic characterization of, 1376
 - chronic neuroblastoma in, 1366
 - death of, parental cancer incidence after, 2237
 - hepatoblastoma in, preoperative chemotherapy for, 172
 - long-term survivor, pulmonary complications in, 2431
 - metastatic sarcoma in, peripheral blood stem cell support for, 1354
 - refractory brain tumors in, fotemustine for, 1294
 - supratentorial neuroglial tumors in, clinical and survival covariates in, 1302
 - survival in, in Europe vs. U.S., 1767
 - thyroid cancer in, 724
- Chinese
 - colorectal cancer in, diet and, 2390
 - p53 codon 72 polymorphism in HPV-related cancers in, 2571
- Cholangiocarcinoma, papillary peripheral, intraductal oncocytic papillary carcinoma and, 2180
- Choriocarcinoma, 5-fluorouracil and actinomycin D for, 1051
- Chronic graft-versus-host disease, in bone marrow transplant recipients, 1076

- Chronic hepatitis C, hepatocellular carcinoma in
human hepatocyte growth factor in, 824
rate of and risk factors for development of, 331
- Chronic leukemia. *See* Leukemia
- Cigarette smoking
bladder cancer in postmenopausal women and, 2316
neoangiogenesis and proliferative response in bronchial epithelium and, 1539
- Cisplatin
for breast cancer, with paclitaxel, 2044
for germ cell tumors, with irinotecan, 1879
hepatic arterial infusion of, for hepatocellular carcinoma with portal vein tumor thrombosis, 588
for hepatoblastoma, in children, 172
for hepatocellular carcinoma, 2038 (letter)
for pancreatic cancer, with gemcitabine, 908
for urothelial cancer, pretreatment prognostic factors and, 751
- c-KIT, absence of, in refractory germ cell tumors, 301
- Clinical trials
in breast cancer, exclusion of elderly from, 989
enrollment in
barriers and facilitators for, 1397 (editorial), 1577, 1584
financial factors in, 1964
vs. hospice care, 1601
participant selection and description for, 950
informed consent in, 2414
- c-myc, in hepatocellular carcinoma, 2346
- Cochlear nerve palsy, radiation-related, 404
- Cognitive function
in acute lymphoblastic leukemia survivors, 2562
in bone marrow transplant recipients, 183
in breast cancer, fatigue and, 2017
pretreatment, as prognostic factor in leptomeningeal disease, 1311
- Collagen IV, in ovarian cancer, 1802
- Colorectal cancer
beta β -catenin in, prognosis and, 2479
diet and, in Singapore Chinese, 2390
folate intake and, 1421
hepatic metastasis in
chemotherapy with cryotherapy and resection for, 2283
intrahepatic invasion from, prognosis and, 105
isolated hepatic perfusion for, 730
prodrug bioactivation and viral oncolysis of, 1171
- hereditary nonpolyposis
genetic testing for, 1848
screening for, by immunohistochemistry vs. microsatellite instability, 2422
- human telomerase reverse transcriptase in, prognosis and, 2103
- insulin-like growth factor I receptor in, 2086
- Ku in, prognosis and, 1199
- metallothionein in, radiation sensitivity and, 1003
- p27^{Kip1} in, prognosis and, 2479
- postoperative serum YKL-40 levels in, survival and, 267
- prevalence of, interstate comparisons of, 430
- proline-directed protein kinase F_A in, 1840
- recurrent, radiotherapy for, 1144
- screening for
NCCRT strategic plan for, 1618
racial vs/ regional differences in, 2211
- telomerase in, 1834
- treatment of, socioeconomic and demographic factors in, 39
- Computed tomography, in lung cancer, in angiogenesis evaluation, 835
- Consent
in clinical trials, 2414
for prostate cancer screening, 1037
- COX-2
in cervical cancer, prognosis and, 531
in endometrial cancer, prognosis and, 801
- Cranial irradiation
cognitive impairment and, in acute lymphoblastic leukemia survivors, 2562
cranial nerve palsy and, 404
pituitary adenoma and, 397
- Cranial nerve palsy, radiation-related, 404
- Curcumin, interleukin 8 inhibition by, 1206
- Cutaneous T-cell lymphoma, interferon- α -2 plus PUVA for, 569
- Cyclin D1 gene, numerical aberration in, in oral cancer, prognosis and, 2152
- Cyclooxygenase-2
in cervical cancer, prognosis and, 531
in endometrial cancer, prognosis and, 801
- Cyclophosphamide
for breast cancer, 228
with radiotherapy, 696
for germ cell tumors, 309
- CYFRA 21-1, in Breast cancer, 670 (letter)
- Cystectomy, radical, specimen evaluation in, 668
- Cytarabine, with idarubicin, for acute lymphoblastic leukemia, in adults, 581
- Cytochrome p450, prodrug bioactivation and oncolysis of liver metastases by, 1171
- Cytokines. *See also* Immunotherapy and specific agents
pro-inflammatory, curcumin inhibition of, 1206
- D**
- Dab2, in ovarian cancer, 1802
- Dacarbazine
for Hodgkin's disease, with radiotherapy, 2169
for uveal melanoma, 2366
- Dactinomycin, with 5-fluorouracil, for gestational trophoblastic tumors, 1051
- Darbopoietin- α , for anemia, in lung cancer, 613
- Data managers, role of in obtaining informed consent in clinical trials, 2414
- Deep vein thrombosis, thalidomide and, 1629
- Demographic factors, in colorectal cancer treatment, 39
- Denmark, hyperparathyroidism and subsequent cancer risk in, 1611

- Dermoscopy, for equivocal melanocytic skin lesions, 1094
 - Desmoid tumors, extraabdominal, imatinib mesylate for, 2373
 - Dexamethasone, for multiple myeloma, 2160
 - Dextromethorphan, for orthopaedic oncology patients, 1164
 - Diabetes mellitus, bladder cancer in postmenopausal women and, 2316
 - Diet, colorectal cancer and, in Singapore Chinese, 2390
 - Diethylstilbestrol, for prostate cancer, in combined vs. monotherapy, 275
 - Diet pills, in pregnancy, acute lymphoblastic leukemia in offspring and, 1786
 - Disabled-2, in ovarian cancer, 1802
 - DNA fragmentation factor 45/ICAD, in esophageal cancer, prognosis and, 2473
 - Docetaxel
 - for head and neck cancer, 1472
 - nonneutropenic infections and, 1326
 - for nonsmall cell lung cancer, with gemcitabine, 1714
 - Doxorubicin
 - for hepatoblastoma, in children, 172
 - for hepatocellular carcinoma, 2038 (letter)
 - for Hodgkin's disease, with radiotherapy, 2169
 - for multiple myeloma, tiple myeloma, 2160
 - pegylated liposomal, with gemcitabine, for advanced cancer, 2223
 - Drug resistance, in hepatoblastoma, *MDR1* gene in, 1795
 - Drug use/abuse, in pregnancy, acute lymphoblastic leukemia in offspring and, 1786
 - Durie-Salmon staging system, MRI in, 1334
- E**
- E-cadherin, in urothelial cancer, 1247
 - Edema
 - arm. *See* Lymphedema
 - periorbital, STI571 and, 881
 - Elderly
 - axillary node dissection in, complications of, 2445
 - breast cancer in
 - adjuvant tamoxifen for, 2465
 - exclusion of clinical trials and, 989
 - hepatocellular carcinoma in, percutaneous ethanol injection for, 816
 - Embolism, pulmonary, thalidomide and, 1629
 - Embolization, arterial, for giant cell tumor of sacrum, 1317
 - Emesis, in chemotherapy, patient perceptions of, 155
 - Endocrine dysfunction, in bone marrow transplant recipients, 1076
 - Endometrial cancer
 - apoptosis in, 1463
 - cyclooxygenase-2 in, prognosis and, 801
 - hypoxia-inducible factors 1 α and 2 α in, prognosis and, 1055
 - stage Ib, myometrial invasion depth in, 316
 - Endometrial carcinoma, laparoscopy for, survival after, 1894
 - Endometrial hyperplasia, apoptosis in, 1463
 - Endostatin
 - in hepatocellular carcinoma, tumor vascularity and, 2188
 - in renal cell carcinoma, 1637
 - Endothelial lesions, premalignant, 5-aminolevulinic acid in diagnosis of, 1234
 - Ependymoma, recurrent spinal cord, etoposide for, 997
 - Ephrin, in osteosarcoma, prognosis and, 862
 - Epidermal growth factor receptors, absence of, in refractory germ cell tumors, 301
 - Epirubicin
 - for breast cancer, 228
 - with gemcitabine, for urothelial cancer, 1444
 - Epoetin- α , for anemia
 - in lung cancer, 613
 - in platinum-based chemotherapy, 2408
 - quality of life and, 888
 - Erectile dysfunction, in prostate cancer, 82, 1773
 - treatment for, 2397
 - Errata, 2581
 - Erythropoietin, recombinant, for anemia
 - in platinum-based chemotherapy, 2408
 - quality of life and, 888
 - Erythropoietin/erythropoietin receptor, in breast cancer, 969
 - Esophageal cancer
 - Barrett esophagus and, 32
 - DNA fragmentation factor 45/ICAD in, prognosis and, 2473
 - incidence of, regional variation in, 2096
 - prediagnosis endoscopy and, 32
 - radiotherapy for, Patterns of Care Study evaluation for, in Japan, 164
 - Smad4 in, 737
 - tumor length and lymph node status in, prognosis and, 1434
 - Esophagus, Barrett, endoscopic screening/surveillance for, 32
 - Esthesioneuroblastoma, intracranial metastatic, treatment of, 243
 - Estrogen replacement therapy, breast cancer and
 - in breast cancer survivors, 1817
 - in Hispanic vs. non-Hispanic women, 960
 - histologic type in, 2455
 - Ethanol injection, for hepatocellular carcinoma, in elderly, 816
 - Ethical communication, in clinical trials, 2414
 - Ethnicity. *See* Race/ethnicity
 - Etoposide
 - for germ cell tumors, 309
 - for small cell lung cancer, 1511
 - for spinal cord ependymoma, 997
 - Ewing sarcoma
 - growth hormone-releasing hormone antagonists for, 1735

metastatic, peripheral blood stem cell support for, in pediatric patients, 1354
Exemestane, pharmacology and pharmacokinetics of, 2006

Exercise, cancer incidence and, 1134

F

Fas/Fas ligand

in myelodysplasia, 1911

in prostatic intraepithelial neoplasia and adenocarcinoma, 296

in testicular cancer, apoptosis and, 73

Fat, body, after androgen blockade for prostate cancer, 2136

Fatigue

anemia-related, in lung cancer, darbopoietin- α for, 613
in breast cancer, 2017

in chemotherapy, patient perceptions of, 155

Fever, nonneutropenic, docetaxel-related, 1326

Financial aspects, of participation in clinical trials, 1064

Fine-needle aspiration biopsy. *See also* Biopsy
ultrasound-guided, of axillary nodes, in breast cancer, 982

¹⁸F-Fluorodeoxyglucose positron emission tomography, in pediatric brain tumors, 1376

5-Fluorouracil

with actinomycin D, for gestational trophoblastic tumors, 1051

for breast cancer, 228

with radiotherapy, 696

for hepatocellular carcinoma, 2038 (letter)

with portal vein tumor thrombosis, 588

for pancreatic cancer, with gemcitabine, 908

for renal cell carcinoma, 1644

Focal adhesion kinase

in BCR-ABL-transfected cells, 440

in oral cancer, 2508

Folate

colorectal cancer risk and, 1421

in head and neck cancer, 2252 (letter)

Follicular thyroid cancer, radioiodine for, 488

Fomustine, for refractory pediatric brain tumors, 1294

Foot, soft tissue sarcoma of, surgery for, 8452

G

Gallbladder carcinoma, postoperative adjuvant chemotherapy for, 1685

Gamma globulin, inhibition of matrix metalloproteinase-9 in macrophages by, 2023

Gastric cancer

of cardia

demographic differences in, 745

incidence of, regional variation in, 2096

prediagnosis endoscopy and, 32

prevalence of, interstate comparisons of, 430

subsite locations and histologic types of, demographic differences in, 745

Gastritis

H. pylori, p53 in, 499

multifocal, demographic differences in, 744

Gelsolin, in urothelial cancer, 1247

Gemcitabine

with epirubicin, for urothelial cancer, 1444

for nasopharyngeal cancer, 2516

for nonsmall cell lung cancer, 340, 1279

with Docetaxel, 1714

with topotecan, 1274

for pancreatic cancer

with camptothecin derivatives, 923

with cetumixab, 923

with cisplatin, 908

with docetaxel, 923

with 5-fluorouracil, 912

new applications of, 941

with pemetrexed, 928

with radiotherapy, 933

with trastuzumab, 923

with pegylated liposomal doxorubicin, for advanced cancer, 2223

for urothelial cancer, pretreatment prognostic factors and, 751

Genetic testing, for hereditary nonpolyposis colon cancer, 1848

Genitourinary neuroendocrine tumors, morphology and treatment of, 1415

Germ cell tumors

extragonadal, treatment outcome in, in Taiwan, 766

HLA Class II genes and, 1857

irinotecan with cisplatin for, 1879

refractory, salvage high-dose chemotherapy for, 309

testicular. *See also* Testicular cancer

bilateral, 1228

late recurrence of, 520

Gestational trophoblastic tumors, 5-fluorouracil and actinomycin D for, 1051

Giant cell tumor, of sacrum, selective arterial embolization for, 1317

Gleevec, periorbital edema and, 881

Gli3 mutations, in medulloblastoma, 28

Glioblastoma, p53 mutations in, survival and, 249

Gliomas

acidosis effects on growth and radiochemosensitivity in, 1113

in vivo models of, chemosensitivity testing in, 641

Gliomatosis cerebri, radiotherapy for, 2027

Glossopharyngeal nerve palsy, radiation-related, 404

Gold marker, real-time tumor-tracking radiotherapy, for lung cancer, 1720

Gonadorelin, for prostate cancer, in combined vs. monotherapy, 275

Graft-versus-host disease, in bone marrow transplant recipients, 1076

Granulocyte colony-stimulating factor, for pediatric metastatic sarcoma, 1354

Grieg syndrome, medulloblastoma in, 28

Grieving parents, cancer in, 2237
 Growth hormone–releasing hormone antagonists, for osteogenic and Ewing sarcomas, 1735
 Gynecologic cancer, quality of life in, assessment of, 2500

H

Hand, soft tissue sarcoma of, surgery for, 8452
 Head and neck, osteogenic sarcoma of, treatment outcome in, 1495
 Head and neck cancer. *See also specific sites and types*
 BPDE-induced lymphocytic 3p21.3 aberrations in, 563
 CCND1 numerical aberration in, prognosis and, 2152
 docetaxel and radiotherapy for, 1472
 focal adhesion kinase in, 2508
 folate and homocysteine levels in, 2252 (letter)
 locally advanced, induction chemotherapy for, 322
 loss of adhesion-regulated proteinase production in, 2524
 lymph node metastasis in, mouse model of, 1663
 perilymphatic interleukin 2 for, 90
 presentation and survival in, in Italy, 540
 pretreatment coping strategies in, 98
 prophylactic retinoids for, 1258
 radiation therapy for
 hypothyroidism after, 673 (letter)
 neck fibrosis after, ultrasound Young Modulus measurement of, 656
 transcriptional expression profiles of, 1482
 weight loss in, prognosis and, 553
 Helicobacter pylori gastritis, p53 in, 499
 Helicobacter pylori infection, biliary cancer and, 1946
 Hemangiopericytoma, clinical outcome in, 1746
 Hematopoietic cancer, after hyperparathyroidism, in Denmark, 1611
 Hematopoietic stem cell transplant
 autologous, for chronic myeloid leukemia, 2339
 cognitive function and, 183
 delirium in, 1971
 endocrine dysfunction after, 1076
 for pediatric metastatic sarcoma, 1354
 Hemoglobin, decreased. *See* Anemia
 Hepatic arterial infusion chemotherapy, for hepatocellular carcinoma with portal vein tumor thrombosis, 588
 Hepatic intrahepatic oncocytic papillary carcinoma, 2180
 Hepatic metastasis
 in colorectal cancer
 chemotherapy with cryotherapy and resection for, 2283
 intrahepatic invasion from, 105
 isolated hepatic perfusion for, 730
 prodrug bioactivation and viral oncolysis of, 1171
 Hepatic perfusion, hyperthermic isolated, for hepatic metastasis, in colorectal cancer, 730
 Hepatitis C
 hepatocellular carcinoma in
 human hepatocyte growth factor in, 824
 insulin-like growth factor in, 2539
 rate of and risk factors for development of, 331

interferon α -2b for, 389
 Hepatoblastoma
 multidrug resistance in, *MDR1* gene in, 1795
 preoperative chemotherapy for, in children, 172
 Hepatocellular carcinoma
 apoptosis in
 gene expression and, 1939
 β 1-integrin-related resistance to, 896
 peroxisome proliferator-activated receptor gamma ligand for, 2243
 Rel/NF-kappaB and, 1696
 c-myc and *Alb1* amplification in, 2346
 hepatitis C-related
 human hepatocyte growth factor in, 824
 insulin-like growth factor in, 2539
 rate of and risk factors for development of, 331
 β 1-integrin in, 896
 intraductal oncocytic, 2180
 percutaneous ethanol injection for, in elderly, 816
 percutaneous radiofrequency ablation therapy with balloon occlusion for, 2353
 peroxisome proliferator-activated receptor gamma ligand for, 2243
 PIAF chemotherapy for, prognostic factors after, 2038 (letter)
 with portal vein tumor thrombosis, hepatic arterial infusion chemotherapy for, 588
 satellite lesions in, 1931
 serum tissue polypeptide specific antigen in, prognosis and, 112
 troglitazone for, 2243
 tumor pressure in, prognosis and, 596
 tumor vascularity in, serum endostatin and, 2188
 Hereditary nonpolyposis colon cancer, screening for genetic testing in, 1848
 by immunohistochemistry vs. microsatellite instability, 2422
 HER/*neu*
 in bladder cancer, prognosis and, 1009
 in breast cancer, in Ashkenazi Jews with BRCA1 mutation, 2068
 in prostate cancer, 1650
 Hispanic women. *See also* Race/ethnicity
 cancer incidence in, 1752
 hormone replacement therapy for, breast cancer and, 960
 HIV infection
 central nervous system lymphoma in, incidence of, 193
 Kaposi sarcoma in
 liposomal tretinoin for, 2555
 paclitaxel for, 147
 HLA Class II genes, testicular cancer and, 1857
 Hodgkin's disease. *See also* Lymphoma
 β 2-microglobulin in, prognosis and, 2534
 chemoradiotherapy for, 2169
 survivors of, lung cancer in, 119
 Homocysteine, in head and neck cancer, 2252 (letter)

- Hormonal dysfunction, in bone marrow transplant recipients, 1076
- Hormone replacement therapy, breast cancer and
in breast cancer survivors, 1817
in Hispanic vs. non-Hispanic women, 960
histologic type in, 2455
- Hormone therapy, for prostate cancer
anemia after, prognosis and, 275
bone density and body fat after, 2136
in combined vs. monotherapy, 209 (editorial), 361
letrozole in, 1865
quality of life and, 287
- Hospice care, vs. clinical trial participation, 1601
- hTERT, in soft tissue tumors, prognosis and, 1127
- Human immunodeficiency virus infection
central nervous system lymphoma in, incidence of, 193
Kaposi sarcoma in
liposomal tretinoin for, 2555
paclitaxel for, 147
- Human leukocyte antigen Class II genes, testicular cancer and, 1857
- Human leukocyte interferon, for uveal melanoma, 2366
- Human papillomavirus infection, oncogenic, Pap smear results and, 2145
- Human papillomavirus-related cancer, p53 codon 72 polymorphism in, in China, 2571
- Human telomerase reverse transcriptase
in colorectal cancer, prognosis and, 2103
in prostate cancer, 2487
in soft tissue tumors, prognosis and, 1127
- Hyaluronic acid-hyaluronidase test, in bladder cancer, 61
- Hydrocortisone, prophylactic intrathecal, for non-Hodgkin's lymphoma, 576
- Hyman hepatocyte growth factor, in hepatitis C-related hepatocellular carcinoma, 824
- Hypercalcemia, in lung cancer, parathyroid hormone-related protein and, 1706
- Hyperparathyroidism, subsequent cancer risk and, in Denmark, 1611
- Hyperthermic isolated hepatic perfusion, for hepatic metastasis, in colorectal cancer, 730
- Hypoglossal nerve palsy, radiation-related, 404
- Hypoplastic myelodysplasia, cyclosporine for, 1911
- Hypothyroidism, postirradiation, 673
- Hypoxia-inducible factors 1 α and 2 α , in endometrial cancer, prognosis and, 1055
- I**
- ICU, length of stay in, in ovarian cancer, 1457
- Idarubicin, with cytarabine, for acute lymphoblastic leukemia, in adults, 581
- Idiopathic pulmonary fibrosis, lung cancer in, ras and p53 in, 624
- Ifosfamide
for germ cell tumors, 309
for head and neck cancer, 322
for hepatoblastoma, in children, 172
- Imatinib mesylate, for extraabdominal desmoid tumors, 2373
- Immunotherapy, for renal cell carcinoma, 1644
- Immunohistochemistry, vs. microsatellite instability, in screening for hereditary nonpolyposis colorectal cancer, 2422
- Immunosuppression
classical Kaposi sarcoma and, 1982
for hypoplastic myelodysplasia, 1911
- Immunotherapy. *See also specific agents*
for chronic hepatitis C, hepatocellular carcinoma development and, 331
with interleukin 2, for renal cell carcinoma, 1045
mechanism of action of, 947 (editorial)
for melanoma, 127, 1101
plus PUVA, for cutaneous T-cell lymphoma, 569
for radiation enteritis, 1151
for renal cell carcinoma, 1045, 1644
- Impotence, in prostate cancer, 82, 1773
treatment for, 2397
- Inactivity, cancer incidence and, 1134
- Incontinence, prostate cancer treatment and, 82
- Inducible nitric oxide synthase, in head and neck cancer, matrix metalloproteinases and, 1902
- Infections, nonneutropenic, docetaxel-related, 1326
- Informed consent
in clinical trials, 2414
for prostate cancer screening, 1037
- Inner-city population. *See also Race/ethnicity*
breast cancer screening for, 8
- Insular thyroid cancer, long-term outcome with, 2076
- Insulin-like growth factor
in hepatitis C-related hepatocellular carcinoma, 2539
for osteogenic and Ewing sarcomas, 1735
- Insulin-like growth factor I receptor, in colorectal cancer, 2086
- β 1-Integrin, in hepatocellular carcinoma, 896
- Integrin, in oral cancer
invasive potential and, 2524
with nodal metastasis, 1663
- Intelligence. *See Cognitive function*
- Intensive care unit, length of stay in, in ovarian cancer, 1457
- Interferon
for chronic hepatitis C, hepatocellular carcinoma development and, 331
human leukocyte, for uveal melanoma, 2366
mechanism of action of, 947 (editorial)
- Interferon- α
for hepatocellular carcinoma, 2038 (letter)
for renal cell carcinoma, subcutaneous vs. IV, 2324
- Interferon- α 2
with interleukin 2, for renal cell carcinoma, 1045
plus PUVA, for cutaneous T-cell lymphoma, 569
- Interferon- α 2b
for melanoma, 1101
pharmacokinetic profile and dosing guidelines for, 389

- Interferon $\alpha 2b$, with all-*trans* retinoic acid, for renal cell carcinoma, 1220
- Interferon-gamma
 - in myelodysplasia, 1911
 - for radiation enteritis, 1151
- Interleukin- α , for renal cell carcinoma, 1644
- Interleukin-2
 - with interferon 2α , for renal cell carcinoma, 1045
 - for metastatic melanoma, 127
 - for renal cell carcinoma, 1644
 - subcutaneous vs. IV, 2324
- Interleukin-2 receptor α , in ovarian cancer, 1886
- Interleukin-6, plasma levels of, in chronic lymphocytic leukemia, prognosis and, 1071
- Interleukin-8, curcumin inhibition of, 1206
- Interleukin-18, serum levels of, in breast cancer, 663
- Intermittent pneumatic compression, for lymphedema, 2260
- Intracranial esthesioneuroblastoma, treatment of, 243
- Intraductal oncocytic papillary carcinoma, hepatic, 2180
- Intravenous gamma globulin, inhibition of matrix metalloproteinase-9 in macrophages by, 2023
- IQ. *See* Cognitive function
- Irinotecan
 - with cisplatin, for germ cell tumors, 1879
 - with paclitaxel and carboplatin, for nonsmall cell lung cancer, 1520
- Isolated hepatic perfusion, for hepatic metastasis, in colorectal cancer, 730
- Italy, head and neck cancer presentation and survival in, 540

J

- Japan, radiotherapy in, Patterns of Care Study evaluation of, 164

K

- Kaposi sarcoma
 - AIDS-related
 - liposomal tretinoin for, 2555
 - paclitaxel for, 147
 - classical, prognosis in, 1982
- Ki-67, in bronchial epithelium, of smokers, 1539
- Ku, in rectal cancer, prognosis and, 1199

L

- Laminin, in ovarian cancer, 1802
- Laparoscopy, for endometrial carcinoma, survival after, 1894
- Latinas. *See also* Race/ethnicity
 - cancer incidence in, 1752
 - hormone replacement therapy for, breast cancer and, 960
- Learning disabilities, in acute lymphoblastic leukemia survivors, 2562
- Leptomeningeal disease, prognosis in, pretreatment cognitive performance and, 1311

- Letrozole
 - pharmacology and pharmacokinetics of, 2006
 - for prostate cancer, 1865
- Letters to editor, 670, 673, 1183, 2038, 2252, 2442, 2577
- Leukemia
 - acute lymphoblastic
 - cognitive outcome in, 2562
 - cytarabine and idarubicin for, in adults, 581
 - parental medication use and, 1786
 - acute myeloid
 - costs of protocol vs. nonprotocol therapy for, 1964
 - vascular endothelial growth factor in, prognosis and, 1911
 - chronic lymphocytic, plasma interleukin-6 levels in, prognosis and, 1071
 - chronic myeloid
 - autologous stem cell transplant for, 2339
 - Ph chromosome and *bcr/bl*-negative, 1673
 - interferon $\alpha 2b$ for, 389
 - lymphoid, survival in, in Europe vs. U.S., 1757
- Leukoplakia, retinoids for, 1258
- Liposomal tretinoin, for AIDS-related Kaposi sarcoma, 2555
- Liver metastasis
 - in colorectal cancer
 - chemotherapy with cryotherapy and resection for, 2283
 - intrahepatic invasion from, 105
 - isolated hepatic perfusion for, 730
 - prodrug bioactivation and viral oncolysis of, 1171
- Lomustine
 - for intracranial esthesioneuroblastoma, 243
 - for uveal melanoma, 2366
- Low T3 syndrome, in bone marrow transplant recipients, 1076
- Lumpectomy
 - choices influencing patient choice of, 1185
 - local recurrence after, vs. new primary, 2059
 - second primary after
 - mortality and, 2051
 - vs. true local recurrence, 2059
- Lung cancer
 - anemia in, darbopoietin- α for, 613
 - angiogenesis in, CT evaluation of, 835
 - in Hodgkin's disease survivors, 119
 - in idiopathic pulmonary fibrosis, ras and p53 in, 624
 - 90K/Mac-2 binding protein in, 1954
 - nonsmall cell
 - brain metastasis in, 605
 - carboplatin for, 1279
 - gemcitabine for, 1279
 - with docetaxel, 1714
 - with topotecan, 1274
 - with vinorelbine, 340
 - irinotecan, paclitaxel and carboplatin for, 1520
 - neuropilin 1/2 coexpression in, prognosis and, 2196
 - novel chemotherapy regimens for, 1279
 - paclitaxel for, 1279
 - in second-line therapy, 1265

- small-volume image-guided radiotherapy for, 1546
- vinorelbine for, 1279
- parathyroid hormone-related protein in, prognosis and, 1706
- real-time tumor-tracking radiotherapy for, gold marker in, 1720
- screening for, overdiagnosis in, 2361
- small cell
 - limited-stage, survival improvement in, 1528
 - sequential topotecan and etoposide for, 1511
- small peripheral adenocarcinoma, modified scar grade in, prognosis and, 2546
- suicidal ideation in, predictors of, 1085
- Lung disease, in pediatric cancer survivors, 2431
- Lymphedema
 - intermittent pneumatic compression for, 2260
 - in older women, 2445
- Lymph node biopsy, sentinel node
 - vs. axillary dissection, in breast cancer, 478
 - in ductal carcinoma in situ, 15
 - unusual sites for, in melanoma, 15
- Lymph node dissection, axillary
 - complications of, in older women, 2445
 - lymphedema after
 - intermittent pneumatic compression for, 2260
 - in older women, 2445
- Lymph node metastasis
 - in esophageal cancer, prognosis and, 1434
 - in oral cancer, mouse model of, 1663
 - in prostate cancer, predictive algorithm for, 1016
- Lymph node metastatic mouse model, gene expression in, 1663
- Lymphoid leukemia, survival in, in Europe vs. U.S., 1757
- Lymphoma
 - central nervous system, incidence of, 193, 1505
 - cutaneous T-cell, interferon- α -2 plus PUVA for, 569
 - Hodgkin's. *See* Hodgkin's disease
 - prevalence of, interstate comparisons of, 430
 - prophylactic intrathecal methotrexate and hydrocortisone for, 576

M

- Magnetic resonance imaging, in multiple myeloma staging, 1334
- Malignant melanoma. *See* Melanoma
- Mammography
 - cancer detected on, provider case volume and outcome in, 704
 - delay to diagnosis after, prognosis and, 2254 (letter)
 - histologic findings and, 470
 - interval adherence to, 219
 - population mortality impact of, 451 (editorial)
 - racial vs. regional differences in, 2221
 - in underserved population, 8
- Mastectomy
 - choices influencing patient choice of, 1185
 - for Paget disease, 1
 - prophylactic bilateral, 236
- Matrix metalloproteinase-9, inhibition of in macrophages, by IV gamma globulin, 2023
- Matrix metalloproteinases
 - in head and neck cancer, 1663, 1902
 - in melanocytic lesions, 1963
- Maximal androgen blockade, for prostate cancer, vs. monotherapy, 209 (editorial)
- Mayo Lung Project Screening Trial, overdiagnosis in, 2361
- MDR1* gene, in hepatoblastoma, multidrug resistance and, 1795
- Medicare recipients, breast cancer treatment in, racial differences in, 1401
- Medulloblastoma
 - calbindin-D_{28k} in, prognosis and, 404
 - Gli3 mutations in, 28
 - histopathologic grading of, 2577 (letter)
- Melanocytic lesions
 - dermoscopic and histopathologic diagnosis of, 1094
 - vascular endothelial growth factor and matrix metalloproteinases 2 and 9 in, 1963
- Melanoma
 - cutaneous
 - dermoscopic and histopathologic diagnosis of, 1094
 - long-term clinical course of, 1286
 - metastatic, clinical and histologic features of, 671 (letter)
 - patient education for, 1554, 1562
 - screening for, 1554, 1562
 - skin self-examination for, performance predictors for, 135
 - vascular endothelial growth factor and matrix metalloproteinases in, 1963
 - interferon α 2b for, 389, 1101
 - metastatic
 - interleukin-2 for, 127
 - unusual sentinel node sites in, 354
 - MIB-1 in, prognosis and, 634
 - uveal, chemoimmunotherapy for, 2366
- Mental health. *See also* Psychosocial issues
 - in early-stage prostate cancer, 54
- Metallothionein, in colorectal cancer, radiation sensitivity and, 1003
- Metastasis
 - cerebral
 - from esthesioneuroblastoma, treatment of, 243
 - in nonsmall cell lung cancer, 605
 - hepatic
 - in colorectal cancer
 - chemotherapy with cryotherapy and resection for, 2283
 - intrahepatic invasion from, 105
 - isolated hepatic perfusion for, 730
 - prodrug bioactivation and viral oncolysis of, 1171
 - leptomeningeal, prognosis in, pretreatment cognitive performance and, 1311
 - lymph node
 - in esophageal cancer, prognosis and, 1434

- in oral cancer, mouse model of, 1663
- in prostate cancer, predictive algorithm for, 1016
- osseous
 - in lung cancer, parathyroid hormone-related protein and, 1706
 - in prostate cancer, 1028
 - urinary calcium excretion in monitoring of, 1182 (letter)
- thyroid, from renal cell carcinoma, 1869
- ¹¹C-Methionine PET, in pediatric brain tumors, 1376
- Methotrexate
 - for breast cancer, 228
 - with radiotherapy, 696
 - prophylactic intrathecal, for non-Hodgkin's lymphoma, 576
- MIB-1
 - in melanoma, prognosis and, 634
 - in soft tissue sarcoma, prognosis and, 843
- Micropapillary serous ovarian carcinoma, 675 (editorial), 677 (editorial)
 - recurrent, cytoreductive surgery for, 791
- Microsatellite instability, vs. immunohistochemistry, in screening for hereditary nonpolyposis colorectal cancer, 2422
- Modified scar grade, in small peripheral adenocarcinoma of lung, prognosis and, 2546
- Monoclonal antibodies
 - cardiotoxicity of, 1592
 - for pancreatic cancer, with gemcitabine, 923
- Morphine
 - consumption of by orthopaedic oncology patients, dextromethorphan and, 1164
 - intravenous, with rapid titration, 203
 - topical, for mucositis, in head and neck cancer, 2230
- Mourning parents, cancer in, 2237
- Mouse, lymph node metastasis model, gene expression in, 1663
- Mouth, premalignant lesions of, retinoids for, 1258
- MSH1/2*, in hereditary nonpolyposis colon cancer, testing for, 1848
- Mucositis, in head and neck cancer, topical morphine for, 2230
- Multidrug resistance, in hepatoblastoma, *MDR1* gene in, 1795
- Multiple myeloma
 - doxorubicin, vincristine, and dexamethasone for, 2160
 - staging of, MRI in, 1334
- Myelodysplasia. *See also specific types*
 - cyclosporine for, 1911
 - vascular endothelial growth factor in, prognosis and, 1911

N

- Narcotic analgesics
 - intravenous, with rapid titration, 203
 - for orthopaedic oncology patients, dextromethorphan and, 1164
 - topical, for mucositis, in head and neck cancer, 2230
- Nasopharyngeal cancer
 - metastatic, chemotherapy for, 2516
 - radiotherapy for, cranial nerve palsy and, 404
- National Colorectal Cancer Roundtable (NCCRT), strategic plan for colorectal screening, 1618
- Nausea and vomiting, in chemotherapy, patient perceptions of, 155
- Neck fibrosis, postirradiation, ultrasound Young Modulus measurement of, 656
- Needle biopsy. *See also Biopsy*
 - ultrasound-guided, of axillary nodes, in breast cancer, 982
- Neuroblastoma
 - chronic, in children, 1366
 - olfactory, with intracranial metastases, treatment of, 243
- Neuroendocrine tumors, genitourinary, morphology and treatment of, 1415
- Neuroglial tumors, supratentorial, clinical and survival covariates in, in children, 1302
- Neuropilin 1/2 coexpression, in nonsmall cell lung cancer, prognosis and, 2196
- Neuropsychological function
 - in acute lymphoblastic leukemia survivors, 2562
 - in bone marrow transplant recipients, 183
 - in breast cancer, fatigue and, 2017
 - pretreatment, as prognostic factor in leptomeningeal disease, 1311
- Neurotoxicity
 - of bone marrow transplant, cognitive function and, 183
 - of thalidomide, 758
- NF-kappaB
 - in apoptosis, in hepatocellular carcinoma, 1696
 - in endometrial hyperplasia/carcinoma, 1463
 - in thyrocyte differentiation, 1827
- 90K/Mac-2 binding protein, in lung cancer, 1954
- Nipple, Paget disease of, conservative surgery vs. mastectomy for, 1
- Nipple aspiration fluid, in breast cancer, protein expression patterns in, 2276
- Nitric oxide
 - in bladder cancer, 2293
 - in breast tumors, 1191
 - serum levels of, in breast cancer, 663
- Nitric oxide synthase, in breast tumors, 1191
- Non-Hodgkin's lymphoma. *See Lymphoma*
- Nonsmall cell lung cancer. *See Lung cancer*
- Nuclear factor kappaB
 - in apoptosis, in hepatocellular carcinoma, 1696
 - in thyrocyte differentiation, 1827

O

- Obesity, after androgen blockade for prostate cancer, 2136
- Older patients
 - axillary node dissection in, complications of, 2445
 - breast cancer in
 - adjuvant tamoxifen for, 2465

- exclusion of from clinical trials and, 989
- hepatocellular carcinoma in, percutaneous ethanol injection for, 816
- Olfactory neuroblastoma, with intracranial metastases, treatment of, 243
- Oophorectomy, length of stay determinants in, 1457
- Opiates
 - intravenous, with rapid titration, 203
 - for orthopaedic oncology patients, dextromethorphan and, 1164
 - topical, for mucositis, in head and neck cancer, 2230
- Oral cancer. *See also* Head and neck cancer
 - CCND1* numerical aberration in, prognosis and, 2152
 - focal adhesion kinase in, 2508
 - loss of adhesion-regulated proteinase production in, 2524
 - lymph node metastasis in, mouse model of, 1663
 - perilymphatic interleukin 2 for, 90
 - prophylactic retinoids for, 1258
 - transcriptional expression profiles of, 1482
 - weight loss in, prognosis and, 553
- Oral lesions, premalignant, retinoids for, 1258
- Orchiectomy, for prostate cancer
 - anemia after, prognosis and, 275
 - bone density and body fat after, 2136
 - in combined vs. monotherapy, 209 (editorial), 361
 - quality of life and, 287
- Organ transplantation. *See also* Transplant
 - central nervous system lymphoma and, 193
- Oropharyngeal cancer. *See also* Head and neck cancer
 - perilymphatic interleukin 2 for, 90
 - prophylactic retinoids for, 1258
- Orthopaedic oncology patients, pain management in, dextromethorphan in, 1164
- Osseous metastasis
 - in lung cancer, parathyroid hormone-related protein and, 1706
 - in prostate cancer, 1028
 - urinary calcium excretion in monitoring of, 1182 (letter)
- Osteopontin, in prostate cancer, 506
- Osteoporosis, after androgen blockade for prostate cancer, 2136
- Osteosarcoma
 - chemotherapy only for, 2202
 - ephrin in, prognosis and, 862
 - growth hormone-releasing hormone antagonists for, 1735
 - of head and neck, treatment outcome in, 1495
 - long-term survivors of, second cancers in, 1728
- Ovarian cancer
 - CA125, tissue polypeptide specific antigen, and soluble interleukin-2 receptor α in, 1886
 - extracellular matrix alterations in, 1802
 - incidence of, racial differences in, 2380
 - micropapillary serous, 675 (editorial), 677 (editorial)
 - recurrent, cytoreductive surgery for, 791
 - prevalence of, interstate comparisons of, 430

- surgery for, length of stay determinants in, 1457
 - topotecan for, 1656
 - vascular endothelial growth factor in, social support and, 808
- Ovarian insufficiency, in bone marrow transplant recipients, 1076

P

- P27^{kip1}, in colorectal cancer, prognosis and, 2479
- p53
 - in bladder cancer, recurrence and, 784
 - in bronchial epithelium, of smokers, 1539
 - in *H. pylori* gastritis, 499
 - in head and neck cancer, matrix metalloproteinases and, 1902
 - in lung cancer, in idiopathic pulmonary fibrosis, 624
 - mutations in, glioblastoma outcome and, 249
- p53 codon 72 polymorphism, HPV-related cancers and, in China, 2571
- Paclitaxel
 - for advanced cancer, with carboplatin, 2000
 - for AIDS-related Kaposi sarcoma, paclitaxel for, 147
 - for breast cancer, with cisplatin, 2044
 - for head and neck cancer, 322
 - for nonsmall cell lung cancer, 1279
 - with irinotecan and carboplatin, 1520
 - in second-line therapy, 1265
 - for urothelial cancer
 - pretreatment prognostic factors and, 751
 - with renal dysfunction, 1022
- Paget disease of nipple, conservative surgery vs. mastectomy for, 1
- Pain management
 - dextromethorphan in, for orthopaedic oncology patients, 1164
 - intravenous morphine with rapid titration for, 203
 - topical, for mucositis, in head and neck cancer, 2230
- Pancreatic cancer
 - curcumin inhibition of interleukin-8 in, 1206
 - gemcitabine for
 - with camptothecin derivatives, 923
 - with cetumixab, 923
 - with cisplatin, 908
 - with docetaxel, 923
 - with 5-fluorouracil, 912
 - new applications of, 941
 - with pemetrexed, 928
 - with radiotherapy, 933
 - with trastuzumab, 923
 - prevalence of, interstate comparisons of, 430
- Pancreaticobiliary carcinoma, postoperative adjuvant chemotherapy for, 1685
- Papillary peripheral cholangiocarcinoma, intraductal oncocyctic papillary carcinoma and, 2180
- Pap smears
 - in oncogenic HPV-infected women, 2145
 - race/ethnicity and, 2211
- Parents, bereaved, cancer in, 2237

- Patient education
for melanoma awareness, 1554, 1562
for prostate cancer screening, 1037
- Patterns of Care Study evaluation, of radiotherapy, in Japan, 164
- Paxillin phosphorylation, in BCR-ABL-transfected cells, 440
- PEG Intron, pharmacokinetic profile and dosing guidelines for, 389
- Pegylated liposomal doxorubicin, with gemcitabine, for advanced cancer, 2223
- Pemetrexed, for pancreatic cancer, with gemcitabine, 928
- Percutaneous ethanol injection, for hepatocellular carcinoma, in elderly, 816
- Percutaneous radiofrequency ablation therapy, for hepatocellular carcinoma, 2353
- Periorbital edema, ST1571 and, 881
- Peripheral blood stem cell support, for pediatric metastatic sarcoma, 1354
- P-glycoprotein, in hepatoblastoma, multidrug resistance and, 1795
- Phenotype selection studies, genotype identification and, 1605
- Physical activity, cancer incidence and, 1134
- PINCH, in tumor-associated stromal cells, 1387
- Pituitary adenomas
prolactin-secreting, clinicopathology of, 258
radiation-related, 397
- Plasminogen activator, urinary-type, in oral cancer, invasive potential and, 2524
- Platinum-based chemotherapy, anemia in, Epoetin- α for, 2408
- Polymerase chain reaction, real-time reverse transcriptase
in colorectal cancer, 2103
in hepatocellular carcinoma, for apoptosis-related gene expression, 1938
- Portal vein tumor thrombosis, in hepatocellular carcinoma, hepatic arterial infusion chemotherapy for, 588
- Positron emission tomography, in pediatric brain tumors, 1376
- Pregnancy, medication use in, acute lymphoblastic leukemia in offspring and, 1786
- Prevalence, interstate comparisons of, 430
- Prognostic factors. *See specific factors and cancers*
- Pro-inflammatory cytokines, curcumin inhibition of, 1206
- Prolactinomas, clinicopathology of, 258
- Proline-directed protein kinase F_A
in bladder cancer, 775
in colon cancer, 1840
- Prostate
biopsy of, age- and volume-adjusted, 2112
neuroendocrine tumors of, morphology and treatment of, 1415
- Prostate cancer
androgen blockade for
anemia after, prognosis and, 275
bone density and body fat after, 2136
vs. monotherapy, 209 (editorial), 361
quality of life and, 287
anemia in, prognosis and, 275
bone metastasis in, 1028
urinary calcium excretion in monitoring of, 1182 (letter)
- brachytherapy for, patient selection for, 513
distant stage, decline in, 870
extracapsular extension of, positive surgical margins as predictor of, 1215
familial, risk factors for, 1346
Fas/Fas ligand in, 298
HER-2/*neu* in, 1650
initial treatment of, 2308
letrozole for, 1865
localized recurrence of, 2302
nodal metastasis in, predictive algorithm for, 1016
osteopontin in, 506
predictive model for, using detailed pathology data, 1451
quality of life in, 54, 287
radiotherapy for, vs. radical prostatectomy, 211 (editorial), 215 (editorial), 281
- screening for
decline in distant stage disease and, 870
informed consent and patient education for, 1037
sexual dysfunction in, 82, 1773, 2397
telomerase reverse transcriptase subunit immunoreactivity in, 2487
treatment complications in, 82
treatment results in
assessment parameters for, 2041 (editorial)
interinstitutional and interspecialty comparison of, 2126
- Prostatectomy
as initial treatment, 2308
radical
complications of, 82
positive margins in, extracapsular extension and, 1215
vs. radiotherapy, 211 (editorial), 215 (editorial), 281
- Prostate specific antigen
localized recurrence and, 2302
in screening
decline in distant stage disease and, 870
informed consent and patient education for, 1037
- Prostatic intraepithelial neoplasia, Fas/Fas ligand in, 296
- Protease-activated receptor-1, in nodal metastasis in oral cancer, 1663
- PSC 833, for multidrug resistance, in hepatoblastoma, 1795
- Psoralen plus ultraviolet light, with interferon- α -2, for cutaneous T-cell lymphoma, 569
- Psychological function
in acute lymphoblastic leukemia survivors, 2562
in bone marrow transplant recipients, 183

- in breast cancer, fatigue and, 2017
- pretreatment, as prognostic factor in leptomeningeal disease, 1311
- Psychosocial issues
 - in ovarian cancer, vascular endothelial growth factor and, 808
 - in prostate cancer, 54
 - in prostate cancer screening, 1037
 - in suicidal ideation in lung cancer, 1087
- Psychosocial issues, in head and neck cancer, 98
- Pulmonary complications, in pediatric cancer survivors, 2431
- Pulmonary embolism, thalidomide and, 1629
- Pulmonary fibrosis, lung cancer in, ras and p53 in, 624
- Pump therapy, for lymphedema, 2260
- PUVA therapy, with interferon- α -2, for cutaneous T-cell lymphoma, 569

Q

- Quality assurance, in radiotherapy, Patterns of Care Study evaluation for, in Japan, 164
- Quality of life
 - anemia and, 888
 - assessment of, in gynecology oncology patients, 2500
 - in bone marrow transplant recipients, cognitive function and, 183
 - chemotherapy side effects and, 155
 - in ovarian cancer, vascular endothelial growth factor and, 808
 - physical activity and, 1134
 - in prostate cancer, 54, 287
- Questionnaire, for quality of life, in gynecologic cancer patients, 2500

R

- Race/ethnicity. *See also specific racial and ethnic groups*
 - breast cancer risk with hormone replacement therapy and, 960
 - in breast cancer screening, 2211
 - breast cancer survival and, 1401, 1988
 - in early-stage disease, 1759
 - in young women, 21
 - breast cancer treatment and, 1401
 - for Asian/Pacific Islanders, 2257 (editorial), 2268
 - in early-stage disease, 1759
 - in cervical cancer screening, 2211
 - in colorectal cancer screening, 2211
 - in gastric cancer, 745
 - ovarian cancer incidence and, 2380
 - in prostate cancer treatment, 2308
- Radiation enteritis, pathophysiology and treatment of, 1151
- Radiation exposure, pituitary adenoma and, 397
- Radiation therapy
 - with chemotherapy
 - for breast cancer, 681
 - for head and neck cancer, mucositis in, topical morphine for, 2230

- chest, complications of, in long-term pediatric survivors, 2431
- clinical trials of. *See* Clinical trials
- for colorectal cancer, socioeconomic and demographic factors in, 39
- cranial
 - cranial nerve palsy and, 404
 - pituitary adenoma and, 397
- cranial irradiation, cognitive impairment and, in acute lymphoblastic leukemia survivors, 2562
- enteritis and, pathophysiology and treatment of, 1151
- for gliomas, acidosis and, 1113
- for gliomatosis cerebri, 2027
- for head and neck cancer, with docetaxel, 1472
- for Hodgkin's disease, with chemotherapy, 2169
- hypothyroidism after, 673
- for intracranial neuroblastoma, 243
- for nasopharyngeal cancer, nasopharyngeal cancer, cranial nerve palsy and, 404
- neck fibrosis after, ultrasound Young Modulus measurement of, 656
- Patterns of Care Study evaluation of, in Japan, 164
- for prostate cancer
 - anemia after, prognosis and, 275
 - complications of, 82
 - as initial treatment, 2308
 - patient selection for, 513
 - vs. radical prostatectomy, 211 (editorial), 215 (editorial), 281
- real-time tumor-tracking, for lung cancer, gold marker in, 1720
- for rectal cancer, in salvage therapy, 1144
- for rhabdomyosarcoma, in adults, 377
- small-volume image-guided, for nonsmall cell lung cancer, 1546
- Radical cystectomy, specimen evaluation in, 668
- Radical prostatectomy
 - complications of, 82
 - as initial treatment, 2308
 - positive margins in, extracapsular extension and, 1215
 - vs. radiotherapy, 211 (editorial), 215 (editorial), 281
- Radiofrequency ablation therapy, for hepatocellular carcinoma, with balloon occlusion, 2353
- Radioiodine, for follicular thyroid cancer, 488
- ras, in lung cancer, in idiopathic pulmonary fibrosis, 624
- Real-time reverse transcriptase polymerase chain reaction
 - in colorectal cancer, 2103
 - in hepatocellular carcinoma, for apoptosis-related gene expression, 1938
- Receptor tyrosine kinases, in refractory germ cell tumors, 301
- Recombinant erythropoietin, for anemia, in lung cancer, 613
- Recombinant human erythropoietin, for anemia
 - in platinum-based chemotherapy, 2408
 - quality of life and, 888
- Recombinant human interleukin. *See* Interleukin

Rectal cancer. *See also* Colorectal cancer

- Ku in, prognosis and, 1199
- metallothionein in, radiation sensitivity and, 1003
- recurrent, radiotherapy for, 1144

Recurrent laryngeal nerve palsy, radiation-related, 404

Rel/NF-kappaB, in apoptosis, in hepatocellular carcinoma, 1696

Renal cell carcinoma

- endostatin levels in, 1637
- immunochemotherapy for, 1644
- interferon 2 α and interleukin 2 for, 1045
- interferon α 2b and all-*trans* retinoic acid for, 1220
- interferon α -2b for, 389
- subcutaneous vs. IV interleukin-2 and interferon α for, 2324
- thalidomide for, 758
- thyroid metastases in, 1869
- vascular endothelial growth factor overexpression and Von Hippel-Lindau tumor suppressor gene in-activation in, 47

Retinoic acid, with interferon α 2b, for renal cell carcinoma, 1220

Retinoids, for premalignant oral lesions, 1258

Reverse transcriptase, human telomerase

- in prostate cancer, 2487
- in soft tissue tumors, prognosis and, 1127

Reverse transcriptase polymerase chain reaction, in hepatocellular carcinoma, for apoptosis-related gene expression, 1938

Rhabdomyosarcoma

- in adults, prognosis of, 377
- metastatic, peripheral blood stem cell support for, in pediatric patients, 1354

rRp450

- of hepatic metastases, 1171
- prodrug bioactivation and oncolysis of liver metastases by, 1171

S

Sacrum, giant cell tumor of, selective arterial embolization for, 1317

Sarcoma. *See also* specific sites and types

- Ewing, growth hormone-releasing hormone antagonists for, 1735

Kaposi

- AIDS-related
- liposomal tretinoin for, 2555
- paclitaxel for, 147
- classical, prognosis in, 1982

- metastatic, peripheral blood stem cell support for, in pediatric patients, 1354

osteogenic. *See* Osteosarcoma

soft tissue

- of hand and foot, surgery for, 8452
- MIB-1 score in, prognosis and, 843
- radiographic response to chemotherapy in, prognosis and, 1120
- telomerase activity in, prognosis and, 1127

Sarcoma cell strains, 1560

Satellite lesions, in hepatocellular carcinoma, 1931

Screening

- for bladder cancer, hyaluronic acid-hyaluronidase and BTA-Stat tests in, 61

for breast cancer

- cancer detected on, provider case volume and outcome in, 704
- delay to diagnosis after, prognosis and, 2254 (letter)
- histologic findings and, 470
- interval adherence to, 219
- population mortality impact of, 451 (editorial)
- racial vs. regional differences in, 2211
- for underserved population, 8

for cervical cancer

- in oncogenic HPV-infected women, 2145
- race/ethnicity and, 2211

for colorectal cancer

- NCCRT strategic plan for, 1618
- racial vs. regional differences in, 2211

for hereditary nonpolyposis colon cancer

- genetic testing in, 1848
- by immunohistochemistry vs. microsatellite instability, 2422

for lung cancer, overdiagnosis in, 2361

for melanoma, 1554, 1562

for prostate cancer

- decline in distant stage disease and, 870
- informed consent and patient education for, 1037

Sedentary lifestyle, cancer incidence and, 1134

Sentinel node biopsy

- in breast cancer, vs. axillary dissection, 478
- in ductal carcinoma in situ, 15
- in melanoma, unusual sites for, 354

Serosus borderline ovarian tumors, aggressive variant of, 675 (editorial), 677 (editorial)

Serum tissue polypeptide specific antigen, in hepatocellular carcinoma, prognosis and, 112

Sexual dysfunction, in prostate cancer, 82, 1773, 2397

SF-36 questionnaire, for quality of life in gynecologic cancer patients, 2500

Signal adapter protein PINCH, in tumor-associated stromal cells, 1387

Singapore, colorectal cancer in, diet and, 2390

Skin cancer. *See also* Melanoma

- skin self-examination for, performance predictors for, 135

Skin lesions, melanocytic

- dermoscopic and histopathologic diagnosis of, 1094
- vascular endothelial growth factor and matrix metalloproteinases 2 and 9 in, 1963

Skin self-examination

- enhancing compliance with, 1554, 1562
- performance predictors for, 135

Smad4, in esophageal cancer, 737

Small cell lung cancer. *See* Lung cancer

Smoking

- bladder cancer in postmenopausal women and, 2316

- neovascularization and proliferative response in bronchial epithelium and, 1539
- Social support. *See also* Psychosocial issues
in ovarian cancer, vascular endothelial growth factor and, 808
- Socioeconomic factors. *See also* Race/ethnicity
in breast cancer screening, 8
in breast cancer survival, 8
in breast cancer treatment, 1401
in colorectal cancer treatment, 39
- Soft tissue sarcoma
of hand and foot, surgery for, 8452
MIB-1 score in, prognosis and, 843
radiographic response to chemotherapy in, prognosis and, 1120
telomerase activity in, prognosis and, 1127
- Soft tissue tumors, telomerase activity in, prognosis and, 1127
- Soluble interleukin-2 receptor α , in ovarian cancer, 1886
- Spinal cord ependymoma, recurrent, etoposide for, 997
- Squamous cell carcinoma. *See also specific sites*
of head and neck. *See* Head and neck cancer
- Staging. *See also specific cancers*
Durie-Salmon system for, MRI in, 1334
- Stem cell transplant
autologous, for chronic myeloid leukemia, 2339
cognitive function and, 183
delirium in, 1971
endocrine dysfunction after, 1076
for pediatric metastatic sarcoma, 1354
- Stereotactic radiation therapy, real-time tumor-tracking, for lung cancer, gold marker in, 1720
- STI571, periorbital edema and, 881
- Stomatitis, in head and neck cancer, topical morphine for, 2230
- Stromal cells, tumor-associated, signal adapter protein PINCH in, 1387
- Substance abuse, in pregnancy, acute lymphoblastic leukemia in offspring and, 1786
- Suicidal ideation, in lung cancer, predictors of, 1085
- Supratentorial neuroglial tumors, clinical and survival covariates in, in children, 1302
- Surgery. *See also specific cancers and procedures*
for soft tissue sarcoma of hand and foot, 852
survivin, in hepatocellular carcinoma, 1938

T

- Taiwan, extragonadal germ cell tumors in, treatment outcome in, 766
- Tamoxifen
vs. anastrozole, for breast cancer, 2442 (letter)
for breast cancer, in older patients, 2465
- T-cell lymphoma, cutaneous, interferon- α -2 plus PUVA for, 569
- Telomerase
in colorectal cancer, 1834
in prostate cancer, 2487
in soft tissue tumors, prognosis and, 1127
- Testicular cancer
Fas/Fas ligand system in, apoptosis and, 73
germ cell
bilateral, 1228
HLA Class II genes and, 1857
irinotecan with cisplatin for, 1879
late recurrence of, 520
refractory
absence of c-KIT and epidermal growth factor receptors in, 301
salvage high-dose chemotherapy for, 309
- Thalidomide
for renal cell carcinoma, 758
venous thromboembolism and, 1629
- Thromboembolism, thalidomide and, 1629
- Thrombosis, portal vein tumor, in hepatocellular carcinoma, hepatic arterial infusion chemotherapy for, 588
- Thymic epithelial tumors, WHO classification of, prognosis and, 421
- Thymidine kinase, in bladder cancer, prognosis and, 2120
- Thyocyte differentiation, tumor necrosis factor α in, 1827
- Thyroid cancer
in children and adolescents, 724
follicular, radioiodine for, 488
after hyperparathyroidism, in Denmark, 1611
insular, long-term outcome with, 2076
thyocyte differentiation in, tumor necrosis factor α in, 1827
- Thyroiditis, in bone marrow transplant recipients, 1076
- Thyroid metastases, from renal cell carcinoma, 1869
- Tissue acidosis, in glioma, effects on growth and radiochemosensitivity in, 1113
- Tissue polypeptide specific antigen
in hepatocellular carcinoma, prognosis and, 112
in ovarian cancer, 1886
- Topotecan
for nonsmall cell lung cancer, with gemcitabine, 1274
for ovarian cancer, 1656
for small cell lung cancer, 1511
- Transcriptional expression profiles, of oral cancer, 1482
- Transforming growth factor β 1, radiation enteritis and, 1151
- Transforming growth factor- β signaling pathway, Smad4 and, in esophageal cancer, 737
- Transitional cell carcinoma. *See* Urothelial cancer
- Transplant
bone marrow
cognitive function and, 183
endocrine dysfunction after, 1076
central nervous system lymphoma and, 193
stem cell
for chronic myeloid leukemia, 2339
cognitive function and, 183
delirium in, 1971
endocrine dysfunction after, 1076
for pediatric metastatic sarcoma, 1354

Trastuzumab
cardiotoxicity of, 1592
for pancreatic cancer, with gemcitabine, 923
Treatment. *See also specific modalities and cancers*
clinical trials for. *See* Clinical trials
Tretinoin, liposomal, for AIDS-related Kaposi sarcoma, 2555
Troglitazone, for hepatocellular carcinoma, 2243
Tumor angiogenesis. *See* Angiogenesis
Tumor-associated stromal cells, signal adapter protein PINCH in, 1387
Tumor necrosis factor- α
in endometrial hyperplasia/carcinoma, 1463
in thyocyte differentiation, 1827
Tumor pressure, in hepatocellular carcinoma, prognosis and, 596

U

Ultrasound, in Young Modulus measurement of postirradiation neck fibrosis, 656
Ultrasound-guided fine-needle aspiration, of axillary nodes, in breast cancer, 982
Ureteral cancer. *See* Urothelial cancer
Urethral cancer. *See* Urothelial cancer
Urinary calcium excretion, in bone metastasis monitoring, in prostate cancer, 1182 (letter)
Urinary incontinence, prostate cancer treatment and, 82
Urinary-type plasminogen activator, in oral cancer, invasive potential and, 2524
Urokinase-type plasminogen activator, in bladder cancer, 2494
Urokinase-type plasminogen activator receptor, in nodal metastasis in oral cancer, 1663
Urothelial cancer
gelsolin and e-cadherin in, 1247
gemcitabine and epirubicin for, 1444
HER/neu in, prognosis and, 1009
after hyperparathyroidism, in Denmark, 1611
pretreatment prognostic factors in, 751
with renal dysfunction, paclitaxel and carboplatin for, 1022
Uterine cancer. *See also* Endometrial cancer

prevalence of, interstate comparisons of, 430
Uveal melanoma, chemoimmunotherapy for, 2366

V

Vagus nerve palsy, radiation-related, 404
Vascular endothelial growth factor. *See also* Angiogenesis
in acute myeloid leukemia, prognosis and, 1911
in melanocytic lesions, 1963
in myelodysplastic syndromes, prognosis and, 1911
in ovarian cancer, social support and, 808
in renal cell carcinoma, 47
endostatin levels and, 1637
Venous thrombosis
portal vein tumor, in hepatocellular carcinoma, hepatic arterial infusion chemotherapy for, 588
thalidomide and, 1629
Vinblastine
for Hodgkin's disease, with radiotherapy, 2169
for renal cell carcinoma, 1644
Vincristine
for breast cancer, 228
for intracranial esthesioneuroblastoma, 243
for multiple myeloma, tiple myeloma, 2160
for uveal melanoma, 2366
Vinorelbine, for nonsmall cell lung cancer, 340, 1279
Viral oncolysis, of hepatic metastases, 1171
Vitamin A, topical, for premalignant oral lesions, 1258
Vomiting, in chemotherapy, patient perceptions of, 155
Von Hippel-Lindau tumor suppressor gene inactivation, in renal cell carcinoma, 47
Vulvectomy, less radical surgery for, results of, 2331

W

Weight loss, in oral/oropharyngeal cancer, prognosis and, 553
WHO classification, of thymic epithelial tumors, prognosis and, 421

Y

YKL-40 levels, in colorectal cancer, survival and, 267
Young Modulus, in measurement of postirradiation neck fibrosis, 656

Authors' Index—Volume 95

A

Aalders, J. G., 2331
 Abbruzzese, J. L., 907, 941
 Abdsalah, S., 458
 Abe, M., 164
 Abe, Y., 2196
 Abell, T. D., 478
 Abend, M., 73
 Achalu, R., 2260
 Acs, G., 969
 Acs, P., 969
 Addamo, A., 2500
 Addicks, K., 2293
 Adelman, L., 1302
 Adler-Storthz, K., 1663
 Agelaki, S., 1326
 Agoff, S. N., 1482
 Aguayo, A., 1923
 Ahmann, F. R., 2136
 Ahn, J., 1457
 Akechi, T., 1085
 Akerley, W., 2000
 Åkerlund, A., 458
 Alaibac, M., 569
 Albertsen, P. C., 361
 Albitar, M., 1071, 1673, 1923
 Alektiar, K. M., 316
 Alexander, H. R., Jr., 1637
 Aliff, T. B., 581
 Allen, B. A., 1848
 Alsharabi, G. M., 1387
 Amagasa, T., 2152
 Amano, H., 1685
 Amariglio, N., 28
 Amato, R. J., 1228
 Ames, F. C., 2059
 Anderson, K. E., 2316
 Ando, E., 588
 Andretta, C., 1911
 Andrieu, J.-M., 2169
 Andriole, G. L., 1239
 Andrulis, I. L., 2068
 Ansari, R., 1629
 Antoine, J. E., 1151
 Antonellini, A., 1520
 Antonescu, C. R., 1746
 Antonuzzo, A., 1444
 Aramaki, M., 105
 Argenziano, G., 1094
 Argnani, M., 309
 Arguedas, M. R., 1434
 Arisawa, K., 331

Armatis, P., 1735
 Aronson, N., 361
 Arquette, M. A., 2223
 Aspelund, F., 1577
 Atzpodien, J., 1045
 Au, S.-K., 488
 Aung, L., 1728
 Aw, T.-C., 2390
 Ayala, A., 2202
 Ayala, A. G., 1228

B

Baba, M., 1539
 Bachner, F., 1334
 Badellino, F., 90
 Bailar, J. C., III, 950
 Baker, L., 2373
 Bakri, K., 1265
 Baldridge, L. A., 1650
 Ball, G., 1673
 Ballo, M. T., 377
 Baquet, C. R., 1457
 Barakat, R. R., 316
 Baretton, G. B., 2086
 Barista, I., 2534
 Barnes, B. C., 1274
 Barnett, G. H., 2027
 Barry, M. J., 287
 Bartl, R., 1334
 Bartlett, N., 989
 Bartlett, N. L., 2223
 Bartolozzi, F., 2500
 Barton, J. H., Jr., 1279
 Baruchel, S., 1294
 Barzan, L., 540
 Baumgartner, K., 960
 Baur, A., 1334
 Baur, R., 82
 Beckett, L., 1009
 Bedi, D. G., 982
 Bedikian, A., 127
 Beechey-Newman, N., 1
 Belfiore, A., 2076
 Bella, M., 228
 Bellanger, A., 155
 Belldegrin, A., 1247
 Benjamin, R. S., 127, 377, 1120, 1317
 Bennett, C. L., 361
 Beny, A., 1644
 Beran, M., 1673
 Bergstrahl, E. J., 1215, 2361

Berlin, J. A., 2455
 Berman, E., 1064
 Bernardini, M. L., 1963
 Bernstein, J. L., 2051
 Bernstein, L., 2455
 Bernstein, Z. P., 2555
 Berrino, F., 430, 1767
 Bessho, A., 1706
 Best, L.-A., 1644
 Beyers, D., 2126
 Biagini, G., 1963
 Bickels, J., 1164
 Biermann, J. S., 2373
 Bisagni, G., 228
 Blackman, S. B., 2465
 Bleijenberg, G., 2017
 Bloch, W., 2293
 Blum, K. A., 2223
 Blum, R., 1101
 Blumenschein, G., Jr., 340
 Blumgart, L. H., 2180
 Blute, M. L., 513, 1028, 1215
 Bode, U., 172
 Boelter, C., 1028
 Boezen, M., 2331
 Bokemeyer, C., 301
 Bolognesi, A., 605
 Boni, C., 228
 Bonomi, M. R., 2230
 Bononi, A., 569
 Boonstra, H., 2331
 Bordone, J., 2339
 Bosman, F. T., 1003
 Bouffet, E., 1294
 Bouwman, D., 21
 Bouzourene, H., 1003
 Boyle, F., 2414
 Boyle, J. O., 1495
 Bozkurt, S., 663
 Braczowski, R., 1735
 Braggio, N., 2500
 Brancorsini, D., 1963
 Branle, F., 641
 Brants, H. A. M., 1421
 Brennan, M. F., 1746
 Brenner, B., 1982
 Brière, J., 2169
 Brierre, J. E., 1274
 Brinton, L. A., 1611
 Brok-Simoni, F., 28
 Brooks, D. R., 1554
 Brooks, S. E., 1457

Brown, R. F., 2414
 Bruhn, R., 2136
 Bruinenberg, M., 1857
 Brunetti, B., 1094
 Brustein, S., 1451
 Bruzzi, P., 228
 Bu, C.-F., 2044
 Bucana, C. D., 1569
 Buchholz, T. A., 2059
 Buchsbaum, J. C., 2302
 Buckley, J. D., 1786
 Bukowski, R. M., 389, 1834, 2160
 Bulajic, M., 1946
 Buller, E. J., 1274
 Bunner, S., 21, 82
 Bürger, D., 172
 Burger, M. P. M., 2331
 Burgess, M. A., 1120
 Burington, B. E., 1971
 Burkman, R. T., 2455
 Burris, H. A., III, 1279
 Busse, P. M., 1472
 Bussi, M., 90
 Butow, P. N., 2414
 Butts, J. A., 1279
 Buzaid, A., 127
 Buzdar, A. U., 2006

C

Cabanillas, F., 2534
 Camby, I., 641
 Camisa, R., 228
 Campo, J. S., 39
 Camps, C., 2408
 Cánepa, C., 2339
 Cantor, K. P., 1611
 Capelli, G., 2500
 Capocaccia, R., 430, 1767
 Capo-Chichi, C. D., 1802
 Caporaso, N., 2539
 Carbone, A., 2539
 Carella, C., 2539
 Carelle, N., 155
 Carney, P. A., 219
 Carolin, K., 21
 Carrasco, E. M., 1605
 Carrasco, H., 2202
 Carretta, A., 605
 Carroll, P. R., 54
 Casarett, D. J., 1601
 Case, M., 1472
 Casella, R., 2494
 Cassasus, P., 2169
 Castle, P. E., 2145
 Casuccio, A., 203
 Catalano, L., 1911
 Cavallo, G., 90
 Ceci, G., 228

Cerchietti, L. C. A., 2230
 Ceresoli, G. L., 605
 Cerhan, J. R., 1504
 Cerroni, L., 1094
 Cerutti, I., 2339
 Chak, A., 32
 Chak, K., 1511
 Chamberlain, M. C., 243, 997
 Chambers, A. F., 506
 Chan, A. T. C., 1511
 Chanan-Khan, A., 2555
 Chandra, S., 8
 Chandrasekhar, S., 1171
 Chang, K.-J., 1840, 2044
 Chang, S. K., 531
 Chang, T.-C., 1827
 Chang, T.-T., 112
 Chang, Y.-F., 1840
 Chano, T., 1954
 Chao, C., 15, 478
 Chao, T.-Y., 2044
 Chaubert, P., 1003
 Che, M., 1228
 Cheah, P. Y., 2479
 Chen, C., 1482
 Chen, G., 420
 Chen, H.-H., 458
 Chen, K.-N., 2571
 Chen, M.-H., 275, 281
 Chen, M. M., 2044
 Chen, Z., 1663, 2136
 Cheng, A.-L., 2044
 Cheng, C., 1482
 Cheng, K., 440
 Cheng, L., 296, 1650
 Cheung, N.-K. V., 1366
 Cheville, J. C., 1028
 Chevreau, C., 2324
 Chiao, P. J., 1696
 Chiarion-Sileni, V., 569
 Chiesa, G., 605
 Chimenti, S., 1094
 Chiocca, E. A., 1171
 Chioni, A., 1444
 Chiu, C.-P., 458
 Chiu, S. K. W., 656
 Chiu, Y.-H., 458
 Cho, N. H., 531
 Choi, C. Y. K., 656
 Choo, P. H., 2479
 Chow, N.-H., 112
 Chow, S.-M., 488
 Choy, H., 613
 Christensen, I. J., 267
 Christensen, M., 2422
 Chronowski, G. M., 2534
 Chua, T., 2390
 Chui, S. Y., 2257

Chung, Y.-C., 1840
 Cinton, C., 267
 Cioca, D. P., 2243
 Cioffi, M., 2539
 Clark, R. S., 2223
 Clauson, J., 1185
 Clayman, G., 322
 Clayman, G. L., 1663
 Coates, R. J., 2455
 Cocconi, G., 228
 Cohen, B. H., 2027
 Cohen, C., 1802
 Cohen, D. S., 1817
 Cohen, H. J., 989
 Colao, A., 1076
 Colby, T. V., 2361
 Colditz, G. A., 1618
 Cole, J. L., 1274
 Coleman, M. P., 1767
 Colevas, A. D., 1472
 Collins, M. M., 287
 Colonna, P., 2169
 Colosimo, C., 2562
 Colowick, A., 613
 Constenla, M., 2408
 Conte, P., 1444
 Cooper, G. S., 32
 Cordon-Cardo, C., 634
 Coristine, M., 1577
 Corkery, E. W., 287
 Corley, D. A., 2096
 Cornelissen, J. J., 183
 Corona, R., 1094
 Cortesina, G., 90
 Corvin, S., 1234
 Coşkun, U., 663
 Costello, R., 1472
 Cote, K., 281
 Coucke, P., 1003
 Coudert, B., 2324
 Coughlin, S. S., 2211
 Cox, J. D., 2534
 Crawford, E. D., 209
 Crawford, J., 989
 Crooks, D., 1584
 Cross, C. K., 1988
 Curley, S. A., 1696
 Cutler, D., 389
 Czene, K., 1346

D

Daikoku, M., 331
 Daling, J. R., 470, 2455
 Dalkin, B. L., 2136
 D'Amico, A. V., 275, 281, 2041
 D'Arrigo, C., 1
 Davis, B., 1028
 Davis, B. J., 513

Davis, R. L., 1203
 Deapen, D., 2455
 Dearnaley, D. P., 520
 Decaestecker, C., 410
 De Cian, F., 2283
 De Giorgi, U., 309
 de Hullu, J. A., 2331
 Delva, R., 2324
 Demuth, F., 2145
 Dengra, C., 2339
 Denis, L., 2126
 De Rosa, G., 1076, 1094
 Dershaw, D. D., 8
 Desablens, B., 2169
 Desai, A. A., 1629
 Desmond, R., 1434
 De Stefani, A., 90
 deVere-White, R., 1009
 Devesa, S. S., 2380
 De Vincenzo, R. I., 2500
 Dhar, D. K., 2188
 Diaz, E., Jr., 322
 Dib, M., 2169
 Di Blasio, B., 228
 Djeridane, M., 2169
 Dong, Q., 1696
 Doody, D. R., 2455
 Dosaka-akita, H., 624
 Dosaka-Akita, H., 1546, 1720
 Douglas, J., 1354
 Douillard, J.-Y., 2324
 Dreicer, R., 1022
 Dreilinger, A. D., 1387
 Duffy, S. W., 458
 Duivenvoorden, H. J., 183
 Dulski, K. M., 440
 Duncan, R. C., 61
 Dutta, S., 1151

E

East, M. J., 127
 Eble, J. N., 296, 1650
 Eckert, G. J., 296, 1650
 Edge, S. B., 2445
 Edieken, B. S., 982
 Edmonds, M. R., 2516
 Edwards, M. J., 15, 478, 1286
 Eeva, M., 1247
 Eftekhari, F., 2202
 Eggert, L., 1401
 Eguchi, K., 331, 1706
 Ehsan, A., 2293
 Eiermann, W., 2006
 Eijenboom, W. M. H., 183
 Einarsson, R., 1886
 Elfring, G. L., 1520
 Eliassen, M. S., 219
 Elliott, D. B., 287

Ellis, L. M., 1569
 Ellis, P. M., 1584
 El-Naggar, A. K., 377
 Eloubeidi, M. A., 1434
 El Shabrawi-Caelen, L., 1094
 Elshaikh, M., 2302
 Elshaikh, M. A., 2027
 Elson, P., 1834, 2160
 Eltabbakh, G. H., 1894
 Engelhardt, D., 2086
 Engelholm, S. A., 1656
 Engelmann, U., 2293
 Epstein, B., 458
 Epstein, J. B., 1258
 Epstein, J. I., 1016
 Erez, A., 28
 Erland, J. B., 1279
 Erlich, N., 1644
 Ernstoff, M., 1101
 Errejon, A., 209
 Erttmann, R., 172
 Escoffre-Barbe, M., 2169
 Eskelin, S., 2366
 Espat, N. J., 1746
 Espina, B. M., 147
 Estey, E. H., 1923
 Estrov, Z., 440
 Esumi, M., 47
 Eton, O., 127
 Eu, K. W., 2479
 Eyster, R. A., 1637

F

Fann, J. R., 1971
 Farwell, D. G., 1482
 Fearn, P., 1451
 Fears, C. L., 2223
 Feig, B. W., 1120, 2059
 Feig, S. A., 451
 Feit, K., 1220
 Feldman, A. L., 1637
 Feldman, G. E., 1618
 Felgenhauer, J., 1354
 Feng, L., 322
 Fenig, E., 1982
 Fentiman, I. S., 1
 Ferrante, P., 309
 Ferrara, G., 1094
 Ferrari, A., 1094
 Ferrazzi, E., 569
 Ferrera, P., 203
 Fink, A. K., 2465
 Fisher, S. G., 135
 Fleming, G., 989
 Fleming, L. E., 1752
 Flemming, P., 1795
 Fletcher, R. H., 1618
 Folger, S. G., 2455

Folkins, A. K., 1009
 Folsom, A. R., 2316
 Fontanesi, J., 2126
 Fontenot, M. F., 1274
 Forman, J., 2126
 Fornage, B. O., 982
 Fornasa, C. V., 569
 Forni, G., 90
 Fossella, F. V., 340
 Fottner, C., 2086
 Fouladi, R. T., 1773, 2397
 Fowler, F. J., Jr., 287
 Fracasso, P. M., 2223
 Francesca, F., 1444
 Franchi, A., 1902
 Franchin, G., 540
 Francisco, M., 322
 Frankel, S. R., 581
 Frankenthaler, R., 1472
 Franquesa, R., 2408
 Franzke, M., 1045
 Fratantonio, S., 1834
 Freeman, H. P., 8
 Freidlin, B., 1528
 Friedman-Birnbaum, R., 1982
 Friedman-Kien, A., 147
 Frimberger, D., 1234
 Fritsche, H., 2276
 Frodis, E., 458
 Frydecka, I., 1886
 Fu, H.-H., 1840
 Fuchs, J., 172, 1795
 Fujii, Y., 2473
 Fujino, S., 1954
 Fujisawa, T., 1539
 Fukabori, Y., 2112
 Fukumori, K., 588
 Fukumoto, S.-I., 1546
 Fukushima, M., 2120
 Fukushima, N., 1931
 Fulfaro, F., 203
 Furuhashi, T., 1206
 Futran, N. D., 1482

G

Gabrys, M., 1886
 Gaeta, G. B., 2539
 Gaitini, D., 1644
 Galli, L., 1444
 Gallo, O., 1902
 Gamel, J. W., 1286
 Gammon, J., 1294
 Ganapathi, M. K., 1834
 Ganapathi, R., 1834
 Gandour-Edwards, R., 1009
 Ganz, P. A., 2465
 Garces, C., 147
 Garcia-Ribas, I., 1605

Garden, A., 322
 Garden, A. S., 377
 Gardner, T. A., 296
 Gatta, G., 1767
 Gatter, K. C., 1055
 Geary, W. A., 1650
 Gebhard, S., 1003
 Geller, A. C., 1554
 George, D., 275, 1864
 George, S. L., 1286
 Georgoulas, V., 1326
 Germanaud, J., 155
 Gershenwald, J. E., 354
 Gertler, R., 2103
 Geurts-Moespot, A., 641
 Gez, E., 1644
 Ghandour, C., 2169
 Ghosh, S., 2524
 Giatromanolaki, A., 1055
 Gidel, C., 1923
 Gilburd, B., 2032
 Gilchrist, B. A., 1554
 Gilcrease, M. Z., 1663
 Giles, F. J., 1923
 Gili, F., 2408
 Gill, P. S., 147, 2555
 Gillenwater, H. H., 1520
 Gilles, F. H., 1302
 Gilliland, F. D., 960
 Ginsberg, J., 2431
 Ginsberg, L., 322
 Giuffrida, D., 2076
 Glaser, S. L., 2268
 Glaspy, J. A., 613
 Glass, A. G., 2145
 Glassman, A., 1673
 Glisson, B. S., 322, 340
 Gobitti, C., 540
 Godfrey, D., 8
 Godwin, A. K., 1802
 Goel, V., 236
 Gokaslan, Z. L., 1317
 Gold, K., 1401
 Goldberg, J. S., 1220
 Goldblum, J., 1834
 Goldbohm, R. A., 1421
 Goldknopf, I. L., 2276
 Goldman, R. D., 2524
 Gomez, F., 2324
 González-Barón, M., 2408
 Goodrich, M. E., 219
 Goodwin, P. J., 2068
 Gooley, T., 1354
 Gorlick, R. G., 1728
 Gorodetzky, A., 1164
 Gorsky, M., 1258
 Grant, R. M., 1294
 Gratz, K. F., 1795

Gray, J. R., Jr., 1279
 Graziano, S., 989
 Greco, F. A., 1279
 Green, K. J., 2524
 Grey, L., 2445
 Gridley, G., 1611
 Gronlund, B., 1656
 Groopman, J., 147
 Groot, K., 1735
 Groupe Français
 d'Immunothérapie, 2324
 Gruman, L. M., 2508
 Grunfeld, E., 1577
 Guan, X.-Y., 2346
 Gudas, L. J., 1220
 Günel, N., 663
 Günel, U., 663
 Guo, M., 2571
 Gurney, J. G., 193
 Guzel, V. B., 1317
 Guzzetta, F., 2562

H

Ha, C. S., 2534
 Haddock, M. G., 513
 Hadley, J., 1401
 Haese, A., 1016
 Haga, Y., 1539
 Hagemester, F. B., 2534
 Hahka-Kemppinen, M., 2366
 Haim, N., 1644
 Hainsworth, J. D., 1279
 Hall, H. L., 2308
 Halpern, A., 1554
 Hamada, H., 331
 Hamed, H., 1
 Hamilton, T. A., 1562
 Hamilton, T. C., 1802
 Hanaoka, J., 1954
 Hanby, A. M., 1
 Hanks, G., 2126
 Hanks, G. E., 164
 Hanlon, A., 2126
 Hansen, D., 2237
 Hansen, H. H., 1656
 Harada, M., 1706
 Harada, T., 1720
 Haraf, D., 98
 Harder, H., 183
 Hargrave, D. R., 1294
 Harila-Saari, A., 1376
 Harlozińska, A., 1886
 Harms, D., 172
 Harrington, W., Jr., 147
 Harris, A. L., 1055
 Harris, J., 1988
 Harwood, B. G., 219
 Hasdemir, O., 663
 Hasselblad, V., 361
 Hatanaka, H., 2196
 Hatono, N., 596
 Hauck, E. W., 73
 Hautmann, S. H., 61
 Hawkins, D. S., 1354
 Hayes, C., 2373
 Hazan, C., 634
 Healey, J. H., 1728
 Hecker, H., 172
 Hedborg-Melander, C., 458
 Hedley-Whyte, E. T., 1302
 Heffess, C. S., 1869
 Heizmann, C. W., 410
 Heller, G., 1064
 Helpap, B., 1415
 Hemminki, K., 1346
 Hendrix, M. J. C., 2508
 Henning, J. M., 54
 Henry, M. L., 1601
 Herbst, R. S., 340
 Herr, H. W., 668
 Hess, K. R., 1120
 Hess, M. A., 2534
 Hidaka, H., 1206
 Hiller, E., 1334
 Hillman, D. W., 513
 Hiraki, A., 1706
 Hirano, M., 596
 Hirata, Y., 2152
 Hironaka, K., 2353
 Hirook, Y., 1938
 Hiroshima, K., 1539
 Hirschman, K. B., 1601
 Hoekstra, H. J., 1857
 Hoffmann, R., 1045
 Hofmann-Wellenhof, R., 1094
 Hofstetter, A., 1234
 Hogdall, C., 1656
 Holford, T., 2051
 Hollema, H., 2331
 Holmberg, L., 458
 Holmqvist, M., 458
 Holzik, M. F. L., 1857
 Homma, Y., 624
 Hong, W. K., 322, 340, 563
 Honke, Y., 164
 Hortobagyi, G. N., 1817
 Horvath, S., 1247
 Horwich, A., 520
 Hoshino, H., 1539
 Hoskins, W. J., 316
 Hosoi, Y., 1199
 Hotte, S. J., 506
 Houston, G. A., 1279
 Hsi, E., 2160
 Hsieh, Y.-C., 1185
 Hsu, C., 2044

Hsu, C.-P., 1840
 Hsueh, S.-F., 1840
 Hu, M., 1569
 Huang, C.-C., 458
 Huang, C.-S., 2044
 Huang, E., 2059
 Huddart, R. A., 520
 Hudgens, S., 1265
 Huland, H., 1016
 Humphrey, P. A., 1239
 Hunger, M., 1795
 Hungerhuber, E., 1234
 Hunt, K. K., 982, 1120, 2059, 2276
 Hussein, M. A., 2160
 Hutchinson, R., 2431
 Huvos, A. G., 1495, 1728
 Hwang, Y.-T., 1401, 2445

I

Iannopollo, M., 1444
 Ibrahim, J., 1101
 Iczkowski, K. A., 2487
 Igarashi, H., 47
 Iida, K., 1127
 Iitsuka, Y., 1051
 Ikeda, H., 164, 258
 Ikeda, M., 1931
 Ikeda, O., 1206
 Ikeguchi, M., 1938
 Ilan, T., 28
 Inomata, M., 105
 Inoue, H., 2196
 Inoue, O., 331
 Inoue, T., 164
 Ishida, H., 47
 Ishigatsubo, Y., 576
 Ishiguro, H., 2473
 Ishiko, T., 1206
 Israel, V. K., 1520
 Ito, K., 2112
 Iuvone, L., 2562
 Iyoda, A., 1539
 Izraeli, S., 28

J

Jacobs, A. D., 923
 Jacobs, G., 2293
 Jaekle, K., 1311
 Jaffe, N., 2202
 Jänne, P. A., 1528
 Janney, C. A., 1504
 Japanese Patterns of Care Study
 1992-1994 Working Group, 164
 Jarnagin, W., 2180
 Jen, Y.-M., 404
 Jenkins, R., 1028
 Jett, J. R., 2361
 Jeuken, J., 641

Jiang, J., 296
 Johansen, C., 1611, 2237
 Johansen, J. S., 267
 Johnson, B. E., 1528
 Johnson, D. H., 1528
 Johnson, L. E., 1401
 Johnson, P., 1511
 Johnson, T. M., 1562
 Jones, J. C. R., 2524
 Jones, M., 1064
 Joslyn, S. A., 1759
 Jung, M. C., 2086
 Jung, M. S., 340
 Jurcic, J. G., 581
 Juven, Y., 397
 Jyrkkö, S., 1376

K

Kadan-Lottick, N. S., 193
 Kaddu, S., 1094
 Kaemmerlen, P., 2283
 Kaibara, N., 1938
 Kakolyris, S., 1326
 Kalaycio, M. E., 581
 Kalbakis, K., 1326
 Kalimo, H., 1376
 Kamachi-satoh, A., 624
 Kamino, H., 634
 Kamohara, H., 1206
 Kamoi, K., 2120
 Kanamori, H., 576
 Kantarjian, H., 1071
 Kantarjian, H. M., 1673, 1923
 Kantoff, P. W., 275, 1864
 Kanz, L., 301
 Kao, C., 296
 Kaplan, R. S., 1504
 Karam, M., 2160
 Karlawish, J. H. T., 1601
 Karlsson, U., 1151
 Karp, D., 1472
 Kasuya, H., 1171
 Karballe, N., 2422
 Kato, H., 1685
 Katon, W. J., 1971
 Kattan, M. W., 1451
 Kaufman, D., 1864
 Kaufmann, M., 1191
 Kausik, S. J., 1215
 Kawa, S., 2243
 Kawakami, T., 2196
 Kawakami, Y., 624
 Kawanishi-Tabata, R., 1834
 Kawano, K., 105
 Kazama, S., 1199
 Kazanis, M., 1864
 Ke, Y., 2571
 Keating, M., 1071

Keating, M. J., 1673, 1923
 Keefe, D. L., 1592
 Kemeny, M., 989
 Kennedy, T., 2000
 Kernan, K., 2126
 Kerner, J., 1037
 Kerner, J. F., 1401
 Kestin, L., 2126
 Khayat, D., 155
 Khuri, F. R., 322, 340
 Kibel, A. S., 1239
 Kies, M. S., 98, 322, 340, 1265
 Kijima, H., 2196
 Killary, A., 1569
 Kim, B. S., 531
 Kim, G. E., 531
 Kim, N., 1834
 Kim, Y. B., 531
 Kimura, M., 2473
 Kindler, H. L., 928
 Kirkwood, J. M., 1101
 Kiss, R., 410, 641
 Kitamura, K., 1546
 Kitano, S., 105
 Kitayama, J., 1199
 Kiura, K., 1706
 Kivelä, T., 2366
 Kiyosawa, K., 2243
 Klein, E. A., 1773, 2302, 2397
 Klein, G., 2339
 Klein, M. J., 1817
 Klimstra, D. S., 2180
 Klotz, T., 2293
 Knight, J. A., 2068
 Knöchel, R., 1234
 Koch, M. O., 296, 1650
 Koch, S., 301
 Kochi, M., 249
 Kodama, F., 576
 Kofoed-Enevoldsen, A., 1611
 Koga, M., 331
 Kohnno, H., 2188
 Kokawa, H., 596
 Kollender, Y., 1164
 Kollmannsberger, C., 301
 Komuro, Y., 1199
 Kondo, H., 2546
 Konings, E. J. M., 1421
 Konishi, S., 2473
 Kontani, K., 1954
 Kopf, A., 634
 Kornblith, A. B., 989
 Kosir, M. A., 21
 Kosuge, T., 1931
 Kotake, T., 1879
 Kothari, A. S., 1
 Kotsakis, A., 1326
 Koukourakis, M. I., 1055

- Kouroussis, C., 1326
 Kovacs, G., 2126
 Koyama, H., 2473
 Koziner, B., 2339
 Kraf, K., 73
 Kramer, K., 1366
 Kraus, D. H., 1495
 Krauss, S., 1629
 Kreissman, S., 1354
 Kriegsmair, M., 1234
 Kris, M. G., 119
 Krishnamurthy, S., 982, 2059, 2276
 Krogh, V., 430
 Krug, L. M., 119
 Krupa, M., 1735
 Ku, S., 440
 Kubo, A., 2096
 Kudo, J., 2473
 Kuerer, H. M., 982, 2059, 2276
 Kupelian, P. A., 1773, 2302, 2397
 Kurago, Z., 2508
 Kuratsu, J., 249
 Kurie, J. M., 340
 Kurokawa, F., 2353
 Kurokawa, K., 2112
 Kuromatsu, R., 588
 Kurtin, P. J., 1504
 Kurzrock, R., 440
 Kusano, N., 2353
 Kushner, B. H., 1366
 Kusminsky, G., 2339
 Kuten, A., 1644
 Kuwabara, Y., 2473
- L**
- Lacotte-Thierry, L., 2169
 Lahat, N., 2032
 Lai, M.-T., 1840
 Lai, R., 1071
 Lai, S.-M., 1827
 Laine, J., 1376
 Lake-Willcutt, B., 1472
 Lamb, C. C., 1472
 Lamerz, R., 1334
 Lamy, T., 2169
 Lang, A., 1569
 Langer, C. J., 613
 Langerman, A., 1185
 Lapinski, R., 2051
 Lara, P. N., Jr., 1009
 LaSalle, J. M., 1009
 Lash, T. L., 2465
 Lassmann, S., 2103
 Lastiri, F., 2339
 Lau, W.-H., 488
 Laughlin, M. M., 389
 Laurberg, S., 2422
 Laurie, S. A., 119
- Lavery, I., 1834
 Law, C.-C., 488
 Law, S. C. K., 488
 Lawrence, T. S., 933
 Lee, J. E., 354
 Lee, J.-H., 1265
 Lee, J. J., 340
 Lee, J. S., 340
 Lee, S.-Y., 2027
 Lee, T. W., 1511
 Lefranc, F., 641
 Legha, S. S., 127
 Lehn, N., 1946
 Leibel, S. A., 1451
 Leibovich, B. C., 1215
 Lejeune, F., 2169
 Leonardi, F., 228
 Leone, L., 2000
 Lerner, S. P., 2494
 Leung, D., 1746
 Leung, S., 656
 Leung, T. W. T., 1511
 Levin, B., 1618
 Leviton, A., 1302
 Levitt, R., 1022
 Lewis, J. J., 1746
 Li, E., 634
 Li, J., 2237
 Li, R., 960
 Li, T., 2571
 Li, Y., 1009
 Liberman, L., 8
 Libutti, S. K., 1637
 Lickley, L., 236
 Lin, J.-C., 404
 Lin, O., 316
 Lin, P. P., 1317
 Lin, P.-W., 112
 Lin, Y.-S., 404
 Linehan, W. M., 1637
 Linn, S., 1982
 Linz-McGilllem, L. A., 2524
 Lippman, S. M., 322
 List, M. A., 98
 Litchy, S., 1279
 Little, C., 1064
 Little, D. J., 377
 Litwin, M. S., 54
 Liu, D. D., 340
 Liu, S. B., 2086
 Liu, Y., 1663, 2431
 Livingston, R. B., 1528
 Ljungberg, E., 458
 Lobysheva, I., 1191
 Locker, P. K., 1520
 Loffredo, M., 281
 Loh, W. Y., 2414
 Lohse, C. M., 1028
- Loibl, S., 1191
 Lokeshwar, V. B., 61
 Lolkema, S., 2331
 Lombardi, G., 1076
 Loöhr, M., 1946
 Looijenga, L. H. J., 301
 Lopez, F., 1834
 Lopez-Berestein, G., 2555
 Lorch, J., 2524
 Lorincz, A. T., 2145
 Lormand, N. A., 1274
 Lowe, L., 1562
 Lowenfels, A. B., 1946
 Lu, C., 340
 Lu, R., 340
 Lu, Y.-S., 2044
 Lu, Z.-M., 2571
 Lubeck, D. P., 54
 Lucarini, G., 1963
 Lucero, G., 2339
 Luciano, L., 1911
 Lyster, H. K., 2257
 Lynch, C., 2051
 Lynch, J., 1037
- M**
- Ma, B. B. Y., 2516
 Ma, W., 258
 Mace, J., 2373
 Maciejewski, J. P., 1911
 MacKinnon, J., 1752
 Maeshima, A., 2546
 Maeshima, A. M., 2546
 Maisonneuve, H., 2169
 Maisonneuve, P., 1946
 Mak, A. F. T., 656
 Mak, S. S. S., 656
 Makino, K., 249
 Mäkipernaa, A., 1376
 Malkowicz, S. B., 281
 Malone, K. E., 2455
 Mandelblatt, J. S., 1401, 2445
 Manola, J., 1022, 1864
 Mansfield, P. F., 354
 Manshouri, T., 1923
 Mantelle, L., 147
 Marangolo, M., 309
 Marchbanks, P. A., 2455
 Maricic, M., 2136
 Mariotti, P., 2562
 Markowitz, S., 61
 Marks, G., 1144
 Marks, J., 1144
 Maronian, N. C., 1482
 Marouani, N., 1164
 Martin, R. C. G., 2180
 Martin, R. C. G., III, 15
 Martinez, A., 2126

Marx, A., 420
 Mascari, R., 1101
 Masini, E., 1902
 Maslak, P. G., 581
 Mass, R., 1650
 Masuda, K., 164
 Matsui, H., 1051
 Matsumine, A., 1127
 Matsumoto, Y., 1199
 Matsuno, Y., 2546
 Matsushiro, T., 1685
 Maushouri, T., 1071
 Mavroudis, D., 1326
 Mayer, F., 301
 Mazzioti, G., 2539
 Mccord, C., 8
 McDonald, J. A., 2455
 McGinn, C., 2373
 McGinn, C. J., 933
 McGregor, D. H., 2487
 Mckee, A., 316
 Mckee, B., 316
 McMasters, K. M., 15, 478
 McNeese, M., 1817
 McNeese, M. D., 2059
 Meerman, G. J. T., 1857
 Meeus, P., 2283
 Mei, Q., 2571
 Mellemkjær, L., 1611
 Meller, I., 1164
 Melzer, K., 634
 Mendenhall, W. M., 488
 Méndez, E., 1482
 Menéndez, P. R., 2230
 Mercadante, S., 203
 Meretyk, S., 1644
 Meric, F., 1120, 2059
 Meropol, N. J., 2445
 Mertens, A. C., 2431
 Metcalfe, K. A., 236
 Metsähonkala, L., 1376
 Mettinger, K., 147
 Meyers, C. A., 1311
 Meyers, F. J., 1009
 Meyers, P., 1495
 Meyers, P. A., 1728
 Michel, K., 1247
 Micheli, A., 430
 Miki, T., 1879, 2120
 Milas, K. M., 1120
 Mildenerberger, H., 172
 Miles, B., 2126
 Miller, D. R., 1554
 Miller, K. C., 2555
 Miller, L. L., 1520
 Miller, M. S., 1637
 Miller, V. A., 119
 Mills, G., 1274

Milone, G., 2339
 Milone, J., 2339
 Milovic, V., 2339
 Milowsky, M. I., 1220
 Minatel, E., 540
 Mings, D., 1584
 Mink, P. J., 2380
 Minn, H., 1376
 Mirza, N. Q., 2059
 Mita, S., 1206
 Mitsunashi, A., 1051
 Miyajima, Y., 596
 Miyamoto, R., 2152
 Miyamoto, S., 2112
 Miyasaka, K., 1546, 1720
 Miyazaki, M., 1206
 Mizutani, Y., 1879, 2120
 Mohiuddin, M., 1144
 Mok, T. S. K., 1511
 Monfardini, S., 569
 Monoski, M. A., 2494
 Montalar, J., 2408
 Monti, G., 309
 Morello, F. A., Jr., 1317
 Morisco, F., 2539
 Morrow, M., 1185
 Motomura, S., 576
 Moul, J. W., 211
 Moura, M. F., 1317
 Mourits, M. J. E., 2331
 Mueller-Hermelink, H. K., 420
 Muhonen, T., 2366
 Muler, I., 28
 Mullen, J. T., 1171
 Müller, P., 1946
 Mullins, C. D., 1457
 Munakata, M., 624
 Munden, R. F., 340
 Munshi, H. G., 2524
 Muss, H., 989
 Mychalczak, B. R., 316
 Myers, J., 322

N

Na, R., 1696
 Nägren, K., 1376
 Nabholz, J.-M., 2006
 Nadel, M., 1618
 Nagakawa, T., 1685
 Nagaoka, S., 2152
 Nagasu, N., 2188
 Nagawa, H., 1199
 Nagel, D., 1334
 Nakabayashi, S., 596
 Nakagawa, K., 1199
 Nakakuki, K., 2152
 Nakamura, H., 249, 1171
 Nakamura, M., 2196

Nakao, M., 1879
 Nakata, K., 331
 Nakayama, T., 1685
 Nanus, D. M., 1220
 Narod, S. A., 236
 Nasuhara, Y., 624
 Natale, R. B., 1520
 National Colorectal Cancer
 Roundtable, 1618
 Native, O., 1644
 Navigante, A. H., 2230
 Neese, L., 1773, 2397
 Négrier, S., 2283, 2324
 Nekarda, H., 2103
 Nepveu, F., 1191
 Newcomb, P. A., 470
 Newcomer, L. M., 470
 Newman, L. A., 21
 Nguyen, N. P., 1151
 Nguyen, P., 2136
 Nguyen, T. V., 553
 Nicholls, J., 520
 Nicolson, G. L., 1569
 Nielsen, H. J., 267
 Niggemann, S., 2293
 Niki, T., 2546
 Nikkanen, V., 2366
 Nimura, Y., 1685
 Nirkin, A., 1164
 Nishimura, M., 1546, 1720
 Nishiwaki, Y., 1085
 Nisihara, H., 624
 Nita, P., 1963
 Niu, J., 1696
 Nixon, A., 1472
 Nolte, I. M., 1857
 Nomoto, T., 1879
 Nonomura, N., 1879
 Norman, A. R., 520
 Norman, S. A., 2455
 Norris, C. M., Jr., 1472
 Northfelt, D. W., 2555
 Nyam, D., 2390

O

O'Brien, S., 1071, 1923
 O'Connor, L., 2268
 Oettle, H., 912
 Offidani, A., 1963
 Ogawa, M., 1206
 Ogura, S., 1546, 1720
 Oh, W., 275
 Oh, W. K., 1864
 Ohi, M., 2112
 Ohkubo, I., 1954
 Ohno, Y., 164
 Ohtsuka, Y., 624
 Ohwada, H., 1539

- Oizumi, S., 1720
Okabe, H., 1954
Okada, K., 47
Okada, S., 1931
Okamura, H., 1085
Okita, K., 2353
Okuda, K., 588
Okumura, M., 596
Okusaka, T., 1931
Okuyama, A., 1879
Oldhafer, K., 172
Olsen, J., 2237
Olson, J. E., 1504
O'Malley, F. P., 2068
O'Neill, B. P., 1504
Onida, F., 1673
Onimaru, R., 1546, 1720
Ono, T., 2188
Oosterhuis, J. W., 301
OPTIONS (Outcomes and Preferences for Treatment in Older Women Nationwide Study) Research Team, 1401
OPTIONS Research Team, 2445
Ordóñez, A., 2408
Orio, F., 1076
Orlandini, C., 1444
Ørntoft, T. F., 2422
Osamura, Y., 2196
Osman, I., 634
Ossiander, E. M., 39
Oudard, S., 2169
Owen, J. B., 164
Ozaki, Y., 1954
Ozcelik, H., 2068
- P**
Pagano, L., 1076
Paglierani, M., 1902
Palotie, A., 1247
Panageas, K. S., 634
Pankratz, V. S., 1028
Pantazis, C. G., 2487
Pantuck, A., 1247
Papadimitrakopoulou, V., 322
Papadimitrakopoulou, V. A., 340
Papadopoulos, N., 127
Papadopoulos, N. E. J., 1120
Papanicolaou, N., 1220
Papiani, G., 309
Park, D. S., 1228
Park, H. C., 531
Park, J., 1354
Park, T. K., 531
Parkes, R. K., 2068
Partin, A. W., 1016
Passoni, P., 605
Patel, S. G., 1495
Patel, S. R., 377, 1120
Pawlik, T. M., 1171
Peace, S., 1752
Peereboom, D. M., 2027
Pelc, K., 410
Pellegriti, G., 2076
Pendergrass, T. W., 1354
Peng, C.-C., 1840
Peny, J., 2324
Pérez-Cachot, P., 2408
Perez-Gracia, J. L., 1605
Peserico, A., 569
Peterman, A., 1265
Peterson, B., 2445
Peterson, B. L., 989
Petrylak, D., 1220
Pfister, D., 1495
Philip, P. A., 908
Phillips, K.-A., 2068
Piccolo, D., 1094
Pickard, A. L., 1611
Pihko, H., 1376
Piotto, E., 155
Pisansky, T. M., 513
Pisters, K. M. W., 340
Pisters, P. W. T., 377, 1120
Pizzocaro, G., 309
Plager, C., 1120
Plonowski, A., 1735
Pochet, R., 410
Pogany, C. E., 2230
Politi, D., 540
Pollock, R. E., 1120, 1569
Polsky, D., 634
Pond, G. R., 2516
Popa, I. E., 1714
Portlock, C. S., 119
Posey, J. T., 61
Posner, M. R., 1472
Potter, J. D., 470, 1786
Potters, L., 1451
Prayson, R. A., 2027
Precone, D. F., 2539
Prehn, A. W., 2268
Pressler, H., 301
Price, P. A., 267
Prieto, V. G., 354
Primdahl, H., 2422
Puppe, B., 420
Purrazzella, R., 1451
Pyo, H. R., 531
Pyrhönen, S., 2366
- Q**
Qiu, X., 440
Quah, S. R., 2390
Quenneville, L. A., 2068
- R**
Rademaker, A. W., 1185
Ragde, H., 2126
Ragland, K. E., 2308
Ragona, R., 90
Rahman, M. A., 2188
Rainey, J. M., 1274
Rakowsky, E., 1982
Rao, J. Y., 1247
Rao, R. D., 1504
Rathore, R., 2000
Ravaud, A., 2324
Raymond, K., 2202
Ready, N., 2000
Reaman, G. H., 1786
Rearden, A., 1387
Rebbeck, T. R., 969
Rechavi, G., 28
Recht, A., 1988
Redd, W., 1037
Reddy, C. A., 2302
Redelotti, R., 569
Reed, C. E., 1434
Regalbuto, C., 2076
Reichert, M., 1113
Reischl, U., 1946
Reiser, M., 1334
Reitz, M., 1045
Reni, M., 605
Renshaw, A. A., 275, 281
Reyes, C. M., 1848
Riccardi, R., 2562
Ricci, P., 1911
Ricci, S., 1444
Richards, T., 1101, 2211
Richie, J. P., 281
Ricks, S., 1482
Ries, L., 430
Ries, L. A. G., 1767
Riess, H., 912
Rimm, A. A., 32
Rinaldi, D. A., 1274
Rini, B. I., 1629
Rios, M. B., 1673
Rivoire, M., 2283
Rizvi, N. A., 1714
Ro, J. S., 1228
Ro, J. Y., 1228
Roach, M., III, 215
Robertson, J. F. R., 2006
Robinson, A., 2339
Robinson, J. K., 135
Robison, L. L., 1786, 2431
Rockson, S. G., 2260
Rogers, A., 1071
Roland, I. H., 1802
Roma, T. E., 581
Rondini, E., 228

Rorke, L. B., 1302
 Rose, E., 389
 Rose, L., 61
 Rosén, M., 458
 Rosenberg, R., 2103
 Rosenblum, M. G., 127
 Rosenzweig, K. E., 119
 Rosmarin, A. S., 1220
 Ross, M. I., 354, 2059
 Rosti, G., 309
 Roth, B. M. C., 2230
 Rothenberger, D. A., 1618
 Roth-Roemer, S., 1971
 Rotoli, B., 1076, 1911
 Rotondi, M., 2539
 Rowley, S. D., 1354
 Rubinov, R., 1644
 Ruchoux, M.-M., 410
 Rudick, V., 1164
 Ruggiero, A., 2562
 Ruiz-Ilundain, M. G., 1605
 Rusch, V. W., 119
 Rush, B. B., 2145
 Rutherford, J. L., 98
 Ryder, K., 1

S

Sadetzki, S., 397
 Saegaert, T., 275
 Safran, H., 2000
 Saiki, S., 1879
 Sakaguchi, S., 596
 Sakamoto, M., 1931
 Sallah, S., 1151
 Salmi, T. T., 1376
 Salmon, I., 641
 Salvagno, L., 569
 Salvioni, R., 309
 Samet, J., 960
 Samonis, G., 1326
 Samson, D. J., 361
 Sancak, B., 663
 Sanchez, K. M., 1650
 Sancho, J. F., 2408
 Sanders, J. E., 1354
 Sandler, A. B., 1520
 Sant, M., 430
 Santucci, M., 1902
 Saporito, G., 2339
 Sardi, I., 1902
 Sariban, E., 410
 Saris, W. H. M., 1421
 Sarris, A. H., 2534
 Sasaki, A., 105
 Sata, M., 588
 Satariano, W. A., 2308
 Sato, A., 2473
 Saville, M. W., 147

Savoldi, L., 228
 Sawai, S., 1954
 Saxman, S., 1528
 Saya, H., 249
 Scadden, D. T., 147
 Scalvenzi, M., 1094
 Scambia, G., 2500
 Scappini, B., 1673
 Scardino, P., 2126
 Schacherer, C. W., 354
 Schaller, M. D., 2508
 Schally, A. V., 1735
 Scheinberg, D. A., 581
 Schell, M. J., 1265
 Schiff, D., 1504
 Schiffman, M., 2145
 Schini-Kerth, V. B., 1191
 Schipani, S., 605
 Schmeller, N., 1234
 Schmelz, H. U., 73
 Schmidt, A., 2293
 Schmitt, B., 361
 Schneede, P., 1234
 Schneider, G. B., 2508
 Schneider-Brachert, W., 1946
 Schover, L. R., 1773, 2397
 Schroeder, G. L., 61
 Schroy, P. S., III, 1618
 Schultz, D., 281
 Schwartz, A., 21
 Schwartz, J. L., 1562
 Schwartz, K., 82
 Schwartz, L., 2180
 Scabas, G. M., 1696
 Scollo, C., 2076
 Scott, C., 1279
 Scott, D. R., 2145
 Sebastiani, L., 309
 Sebban, H., 2283
 Sebo, T. J., 1028, 1215
 Sedlacek, P., 1886
 See, W., 1022
 Seeff, L., 2211
 Seet, B. L., 499
 Segawa, Y., 1706
 Seidenfeld, J., 361
 Seigler, H. F., 1286
 Seki, K., 1051
 Sekiya, S., 1051
 Seligson, D., 1247
 Selleri, C., 1076, 1911
 Selli, C., 1444
 Selvin, S., 2308
 Selzer, M. G., 61
 Semple, J., 236
 Sen, R., 2524
 Senie, R., 2445
 Seow, A., 2390

Seow-Choen, F., 2479
 Sera, F., 1094
 Servaes, P., 2017
 Seto, M., 1127
 Setoguchi, T., 1206
 Severson, R. K., 82, 1786
 Shah, J. P., 1495
 Shaha, A. R., 1495
 Shahidi, M., 520
 Sham, J. S. T., 2346
 Shapiro, S., 2032
 Shariat, S. F., 2494
 Shelby, R., 1037
 Shelton, G., 1220
 Shepherd, F. A., 1528
 Sherman, A. M., 1311
 Sherman, M. E., 2145, 2380
 Sheta, E. A., 2276
 Shi, W., 1728
 Shia, J., 1746
 Shiba, M., 1539
 Shibata, Y., 2473
 Shibuya, K., 1539
 Shim, S. J., 531
 Shimada, K., 1931
 Shimizu, S., 1720
 Shimzu, S., 1546
 Shin, D. M., 322, 340
 Shinoda, N., 2473
 Shirahashi, H., 2353
 Shiraishi, S., 249
 Shirato, H., 1546, 1720
 Shoenfeld, Y., 2032
 Shorter, N. A., 1728
 Shu, X. O., 1786
 Siewert, J.-R., 2103
 Sijmons, R. H., 1857
 Sikov, W., 2000
 Silliman, R. A., 2465
 Simon, M., 2169
 Simon, M. S., 2455
 Simonetti, O., 1963
 Singh, B., 1495
 Singletary, S. E., 982, 1817, 2059
 Sinn, H.-P., 1191
 Siu, L. L., 2516
 Sivridis, E., 1055
 Sklar, C., 2431
 Skluzacek, M. C., 193
 Slawin, K., 2126
 Sleijfer, D. T., 1857
 Slezak, J., 1215
 Smith, E. R., 1802
 Smith, F. P., 1714
 Smith, M. R., 1864
 Smith, R. A., 458, 1618
 Smith, T. L., 1673, 1817
 Sneige, N., 982

Sobel, E., 2032
Sobel, E. L., 1302
Sober, A. J., 1554
Socinski, M. A., 1265, 1520
Soda, Y., 2188
Soloway, M. S., 61
Sommer, F., 2293
Sondak, V., 2373
Sondak, V. K., 947, 1562
Sonneveld, D. J. A., 1857
Sonoda, J., 1127
Soraru, M., 569
Sørensen, F. B., 2422
Sørensen, S., 267
Sorvillo, F., 2539
Sosman, J., 1101
Souglakos, J., 1326
Soyer, H. P., 1094
Sparwasser, C., 73
Spirtas, R., 2455
Spitalny, G. M., 54
Spitz, M. R., 563
Sprenger, S., 641
Squarrito, S., 2076
Srkalovic, G., 2160
Stäbler, A., 1334
Stack, M. S., 2524
Stadler, W. M., 1629
Staibano, S., 1094
Stallings, F., 2211
Staradub, V. L., 1185
Statkevich, P., 389
Stein, A., 1644
Stein, A. L., 8
Steinbach, J. P., 1113
Steinberg, S. M., 1637
Stenbäck, F., 1463
Stenbeck, M., 458
Stepp, H., 1234
Stevens, G. H. J., 2027
Stewart, K., 1714
Stewart, S., 2268
Stief, C., 1045
Stimec, B., 1946
Stitt, L., 506
Storer, B. E., 470
Stornauiuolo, G., 2539
Stovall, M., 2431
Stracks, J., 98
Straughan, P. T., 2390
Strebhardt, K., 1191
Stricker, D., 2103
Stroebe, P., 420
Strom, B. L., 2455
Strom, E. A., 2059
Study Committee of the
Cooperative Pediatric Liver
Tumor Study Hb 94 for the

German Society for Pediatric
Oncology and Hematology, 172
Study Group of Surgical Adjuvant
Therapy for Carcinomas of the
Pancreas and Biliary Tract, 1685
Sugiura, H., 2473
Suh, C. O., 531
Suh, J. H., 2027
Sulkes, A., 1982
Suman, V. J., 513
Sumie, S., 588
Summanen, P., 2366
Sumner, W. E., III, 354
Sundbom, A., 458
Supra, P., 1113
Suzuka, K., 1051
Suzuki, K., 2112
Suzuki, N., 1199
Suzuki, S., 1206
Swanson, G. M., 950
Sweeney, C. J., 1650
Sweep, F., 641
Syrjala, K. L., 1971
Szuba, A., 2260

T

Tabár, L., 458
Tada, K., 249
Takada, T., 1685
Takahashi, T., 624
Takigawa, N., 1706
Talamini, R., 540
Tallman, M. S., 581
Talpa, M., 440
Tamboli, P., 1228
Tan, B. R., 2223
Tan, K. B., 499
Tanabe, K. K., 1171
Tanaka, E., 2243
Tanaka, M., 588
Tanaka, N., 1051
Tanimoto, M., 1706
Tanisada, K., 164
Tannock, I. F., 2516
Tapanainen, J. S., 1463
Tariq, N., 1294
Tarkkanen, A., 2366
Tattersall, M., 1397
Tauchmanová, L., 1076
Tavaré, C. J., 1302
Tawfik, O. W., 2487
Taylor, K. L., 1037
Tazelaar, H. D., 2361
Teichmann, B., 1795
Tendler, C., 389
Teramoto, K., 1954
Terashita, Y., 2473
Terdiman, J. P., 1848

Teschendorf, B., 1064
Teshima, T., 164
Tezuka, N., 1954
Thaler, H., 1728
The Cancer and Leukemia Group B,
989
The Childhood Brain Tumor
Consortium, 1302
The, M., 499
The Scientific Program Committee,
1134
The Tumor and Angiogenesis
Research Group, 1055
Theriault, R. L., 1817
Tholin, M., 458
Thomas, D., 2373
Thompson, D. S., 1279
Thompson, L. D., 1869
Thompson, T., 2308
Thompson, T. D., 2211
Thompson, W. D., 2051
Thomson, B., 1354
Thuillier, A., 155
Tindall, D., 1028
Tishler, R. B., 1472
Tohara, K., 596
Tokunaga, T., 2196
Tomaszewski, J. E., 281
Tomita, N., 576
Tomoda, R., 1127
Topol, B., 2268
Toyoaki, T., 1539
Trapido, E., 1752
Traullé, C., 2169
Travis, W. D., 2361
Trent, J. C., II, 1569
Trentham-Dietz, A., 470
Tripathi, A., 2316
Tsai, Y.-F., 1827
Tsangaris, T., 2445
Tsumuki, H., 1127
Tsunno, N., 1199
Tu, D.-G., 112
Tubbs, R., 1834
Tucker, S. L., 2534
Tulpule, A., 147
Tung, T.-S., 458
Turrisi, R. J., 135

U

Uchida, A., 1127
Uchitomi, Y., 1085
Ueki, T., 596
Ueno, H., 1931
Ueoka, H., 1706
Ueyama, Y., 2196
Ulbright, T. M., 296
Ulm, K., 2103

Unger, P., 1265
 Ursin, G., 2455
 Usai, A., 90
 Ushio, Y., 249
 Utriainen, M., 1376
 Utriainen, T., 1376
 Uzawa, N., 2152

V

Vaccher, E., 540
 Van Beuningen, D., 73
 van Dalen, A., 1886
 van den Bent, M. J., 183
 van den Brandt, P. A., 1421
 Van Den Eeden, S. K., 2308
 van der Graaf, W. T. A., 1857
 Vanderveer, L., 1802
 van der Zee, A. G. J., 2331
 VanEenwyk, J., 39
 Van Gool, A. R., 183
 Varga, J. L., 1735
 Vargas, M., 1220
 Varma, D. G. K., 1120
 Vaskivuo, T. E., 1463
 Vassilopoulou-Sellin, R., 1817
 Vaughn, D. J., 1022
 Venkatraman, E., 316
 Verdecchia, A., 430
 Verhagen, C. A. H. H. V. M., 2017
 Verma, A., 969
 Vernon, S. W., 1618
 Verstovsek, S., 1923
 Vicini, F. A., 2126
 Vigier, M., 2169
 Vigneri, R., 2076
 Villa, E., 605
 Villari, P., 203
 Vincent, S., 410
 Visapaa, H., 1247
 Vlachonikolis, J., 1326
 Vocaturo, V., 1444
 Vogelzang, N. J., 1629
 Voigt, L. F., 2455
 Vokes, E. E., 98
 von Minckwitz, G., 1191
 Von Schweinitz, J. R. D., 172

W

Wacholder, S., 2145
 Wada, H., 2120
 Wallace, S., 1317
 Wandert, T., 1045
 Wang, C.-Y., 1827
 Wang, J. Y. J., 440
 Wang, S.-T., 112
 Wang, T. S., 1562
 Wang, Y., 2346
 Wang-Rodriguez, J., 1387

Warmann, S., 1795
 Warneke, C. L., 1773, 2397
 Watanabe, T., 1199
 Watson, R., 61
 Webb, C., 1279
 Weber, K. L., 1317
 Weber, M. M., 2086
 Weber, S., 1191
 Weeks, J. C., 2445
 Weidner, W., 73
 Wein, A., 281
 Weinbroum, A. A., 1164
 Weinl, P., 172
 Weiss, J. E., 219
 Weiss, L. K., 2455
 Weiss, M. A., 581
 Weissmann-Brenner, A., 1982
 Weller, M., 1113
 Weltfriend, S., 1982
 Wen, W., 1786
 Wender, R., 1618
 Wendtner, C., 1334
 Wen-Hu, C., 420
 Wenig, B. M., 1869
 Werner, M., 2103
 West, D. W., 2268
 Weymuller, E. A., Jr., 1482
 Wheeler, J., 989
 Whelan, T. J., 1584
 White, M., 21
 Whiteside, T. L., 1101
 Whittington, R., 281
 Wieand, S., 1101
 Wiege, M., 458
 Wikman, F., 2422
 Wilcox, C. M., 1434
 Wilder, R. B., 2534
 Wilding, G., 1022
 Wilkinson, J. D., 1752
 Wilson, L. S., 1848
 Wilson, S. M., 506
 Wilson, T. M., 513
 Wilt, T. J., 361
 Wingo, P. A., 2455
 Winquist, E. W., 506
 Wohler-Torres, B., 1752
 Wolden, S., 1495
 Wolf, G., 1191
 Wolf, I. H., 1094
 Wong, H., 1511
 Wong, S. L., 15, 478
 Wood, L., 2160
 Woodruff, J. M., 1746
 Wright, J. R., 1584
 Wu, H.-M., 458
 Wu, M.-C., 2346
 Wu, Q.-J., 2571
 Wu, W.-Q., 2346

Wu, X., 563
 Wu, Y., 2487

X

Xing, H.-P., 2571
 Xu, X.-X., 1802

Y

Yadlapati, S., 1274
 Yamada, T., 2546
 Yamaguchi, E., 2188
 Yamamoto, J., 1931
 Yamamoto, T., 2112
 Yamanaka, H., 2112
 Yamanoi, A., 2188
 Yamasaki, S., 1931
 Yamasaki, T., 2353
 Yamashita, F., 588
 Yamazaki, H., 2196
 Yamazaki, K., 1546, 1720
 Yamazaki, T., 1127
 Yamazawa, K., 1051
 Yan, Y., 1239
 Yancik, R., 430
 Yang, C.-C., 1840
 Yang, D.-H., 1802
 Yang, J. C., 1637
 Yang, S.-D., 1840
 Yano, K., 331
 Yano, M., 331
 Yano, Y., 588
 Yao, J., 2479
 Yao, T., 596
 Yao, W.-J., 112
 Yasko, A. W., 1317
 Yasuda, H., 1685
 Yasuda, K., 105
 Yasui, Y., 470, 2431
 Yates, S., 1265
 Yatsubashi, H., 331
 Yau, S., 488
 Yen, M.-F., 458
 Yeo, W., 1511
 Yeoh, K. G., 499
 Yilmaz, A., 2180
 Yim, A., 1511
 Yoneda, T., 1706
 Yong, J., 420
 Yoon, S. S., 1171
 Yoshida, O., 2120
 Yoshiki, T., 1954
 Yoshimoto, T., 258
 Yoshizawa, K., 2243
 Yu, D., 1569
 Yu, K. H., 1511
 Yuan, X. H., 1663
 Yuan, Z., 32
 Yueh, B., 553

Yuen, K.-T., 488
Yutani, S., 588

Z

Zaak, D., 1234
Zaderajko, M. A., 2230
Zagars, G. K., 377
Zaharias, R., 2508
Zalupski, M. M., 933

Zannini, P., 605
Zarour, H. M., 1101
Zee, B., 656, 1511
Zelevsky, M. J., 316
Zhang, L., 1569
Zhang, P. J., 969
Zhang, S., 296, 1650
Zhang, W., 127, 2346
Zhang, X., 1663
Zhang, Z., 1554

Zhao, L. P., 1482
Zheng, Y., 656
Zheng, Y.-L., 563
Zhong, W.-B., 1827
Zhu, Y., 563
Zidan, J., 1644
Zincke, H., 513, 1215
Zinner, R., 340
Zippe, C., 1773, 2302, 2397
Zitzelsberger, L., 1577

